Codexis (CDXS) 10-Q 3 Nov 23 2023 Q3 Quarterly report Financial data

Cover Page

Cover Page - shares	9 Months Ended
	Sep. 30, 2023	Oct. 30, 2023
Cover [Abstract]
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Sep. 30, 2023
Document Transition Report	false
Entity File Number	001-34705
Entity Registrant Name	Codexis, Inc.
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	71-0872999
Entity Address, Address Line One	200 Penobscot Drive
Entity Address, City or Town	Redwood City
Entity Address, State or Province	CA
Entity Address, Postal Zip Code	94063
City Area Code	650
Local Phone Number	421-8100
Title of 12(b) Security	Common Stock, par value $0.0001 per share
Trading Symbol	CDXS
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Accelerated Filer
Entity Small Business	false
Entity Emerging Growth	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		69,830,199
Entity Central Index Key	0001200375
Amendment Flag	false
Document Fiscal Year Focus	2023
Document Fiscal Period Focus	Q3
Current Fiscal Year End Date	--12-31

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets (Unaudited) - USD ($) $ in Thousands	Sep. 30, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 74,577	$ 113,984
Restricted cash, current	991	521
Financial assets:
Accounts receivable	11,629	31,904
Contract assets	1,936	2,116
Unbilled receivables	5,661	7,016
Total financial assets	19,226	41,036
Less: allowances	(133)	(163)
Total financial assets, net	19,093	40,873
Inventories	2,305	2,029
Prepaid expenses and other current assets	5,402	5,487
Assets held for sale	646	0
Total current assets	103,014	162,894
Restricted cash	1,062	1,521
Investment in non-marketable equity securities ($0 and $13,921 with a related party)	18,013	20,510
Right-of-use assets - Operating leases, net	13,895	39,263
Property and equipment, net	15,282	22,614
Goodwill	2,463	3,241
Other non-current assets	726	350
Total assets	154,455	250,393
Current liabilities:
Accounts payable	3,098	3,246
Accrued compensation	10,521	11,453
Other accrued liabilities	8,796	15,279
Current portion of lease obligations - Operating leases	6,764	5,360
Deferred revenue	9,236	13,728
Total current liabilities	38,415	49,066
Deferred revenue, net of current portion	10,100	16,881
Long-term lease obligations - Operating leases	13,215	38,278
Other long-term liabilities	1,219	1,371
Total liabilities	62,949	105,596
Commitments and Contingencies (Note 10)
Stockholders' equity:
Preferred stock, $0.0001 par value per share; 5,000 shares authorized, none issued and outstanding	0	0
Common stock, $0.0001 par value per share; 200,000 shares authorized; 69,827 shares and 65,811 shares issued and outstanding as of September 30, 2023 and December 31, 2022, respectively	6	6
Additional paid-in capital	581,838	566,081
Accumulated deficit	(490,338)	(421,290)
Total stockholders' equity	91,506	144,797
Total liabilities and stockholders' equity	$ 154,455	$ 250,393

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) - USD ($) $ in Thousands	Sep. 30, 2023	Dec. 31, 2022
Investment at cost basis	$ 18,013	$ 20,510
Preferred stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Preferred stock, shares authorized (in shares)	5,000,000	5,000,000
Preferred stock, shares issued (in shares)	0	0
Preferred stock, shares outstanding (in shares)	0	0
Common stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Common stock, shares authorized (in shares)	200,000,000	200,000,000
Common stock, shares, issued (in shares)	69,827,000	65,811,000
Common stock, shares, outstanding (in shares)	69,827,000	65,811,000
Related Party
Investment at cost basis	$ 0	$ 13,921

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations (Unaudited) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Revenues:
Total revenues	$ 9,277	$ 34,470	$ 43,582	$ 108,215
Costs and operating expenses:
Cost of product revenue	2,249	9,786	9,947	29,577
Research and development	13,662	21,821	47,651	60,410
Selling, general and administrative	12,302	13,499	41,066	39,859
Restructuring charges	3,140	0	3,284	0
Asset impairment and other charges	9,984	0	9,984	0
Total costs and operating expenses	41,337	45,106	111,932	129,846
Loss from operations	(32,060)	(10,636)	(68,350)	(21,631)
Interest income	1,056	436	3,266	618
Other income (expense), net	(3,895)	216	(3,930)	150
Loss before income taxes	(34,899)	(9,984)	(69,014)	(20,863)
Provision for income taxes	9	8	34	125
Net loss	$ (34,908)	$ (9,992)	$ (69,048)	$ (20,988)
Net loss per share, basic (in dollars per share)	$ (0.50)	$ (0.15)	$ (1.02)	$ (0.32)
Net loss per share, diluted (in dollars per share)	$ (0.50)	$ (0.15)	$ (1.02)	$ (0.32)
Weighted average common stock shares used in computing net loss per share, basic (in shares)	69,466	65,426	67,670	65,271
Weighted average common stock shares used in computing net loss per share, diluted (in shares)	69,466	65,426	67,670	65,271
Product revenue
Revenues:
Total revenues	$ 5,395	$ 28,042	$ 24,807	$ 93,376
Research and development revenue
Revenues:
Total revenues	$ 3,882	$ 6,428	$ 18,775	$ 14,839

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Operations (Unaudited) (Parenthetical) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Revenues	$ 9,277	$ 34,470	$ 43,582	$ 108,215
Restructuring charges	3,140	0	3,284	0
Product revenue
Revenues	5,395	28,042	24,807	93,376
Product revenue | Related Party
Revenues	0	215	0	358
Research and development revenue
Revenues	3,882	6,428	18,775	14,839
Research and development revenue | Related Party
Revenues	$ 0	$ 1,000	$ 0	$ 1,245

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Stockholders' Equity (Unaudited) - USD ($) $ in Thousands	Total	Common Stock	Additional Paid-in Capital	Accumulated Deficit
Beginning balance (in shares) at Dec. 31, 2021		65,109,000
Beginning balance at Dec. 31, 2021	$ 164,391	$ 6	$ 552,083	$ (387,698)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Exercise of stock options (in shares)	252,100	252,000
Exercise of stock options	$ 612		612
Release of stock awards (in shares)		332,000
Employee stock-based compensation	11,467		11,467
Non-employee stock-based compensation	133		133
Taxes paid related to net share settlement of equity awards (in shares)		(80,000)
Taxes paid related to net share settlement of equity awards	(1,484)		(1,484)
Net loss	(20,988)			(20,988)
Ending balance (in shares) at Sep. 30, 2022		65,613,000
Ending balance at Sep. 30, 2022	154,131	$ 6	562,811	(408,686)
Beginning balance (in shares) at Jun. 30, 2022		65,494,000
Beginning balance at Jun. 30, 2022	159,459	$ 6	558,147	(398,694)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Exercise of stock options (in shares)		77,000
Exercise of stock options	180		180
Release of stock awards (in shares)		47,000
Employee stock-based compensation	4,516		4,516
Non-employee stock-based compensation	15		15
Taxes paid related to net share settlement of equity awards (in shares)		(5,000)
Taxes paid related to net share settlement of equity awards	(47)		(47)
Net loss	(9,992)			(9,992)
Ending balance (in shares) at Sep. 30, 2022		65,613,000
Ending balance at Sep. 30, 2022	154,131	$ 6	562,811	(408,686)
Beginning balance (in shares) at Dec. 31, 2022		65,811,000
Beginning balance at Dec. 31, 2022	$ 144,797	$ 6	566,081	(421,290)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Exercise of stock options (in shares)	214,284	214,000
Exercise of stock options	$ 422		422
Release of stock awards (in shares)		787,000
Employee stock-based compensation	7,808		7,808
Issuance of common stock, net of issuance costs (shares)		3,080,000
Issuance of common stock, net of issuance costs	7,931		7,931
Taxes paid related to net share settlement of equity awards (in shares)		(65,000)
Taxes paid related to net share settlement of equity awards	(404)		(404)
Net loss	(69,048)			(69,048)
Ending balance (in shares) at Sep. 30, 2023		69,827,000
Ending balance at Sep. 30, 2023	91,506	$ 6	581,838	(490,338)
Beginning balance (in shares) at Jun. 30, 2023		69,804,000
Beginning balance at Jun. 30, 2023	124,131	$ 6	579,555	(455,430)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Release of stock awards (in shares)		23,000
Employee stock-based compensation	2,283		2,283
Net loss	(34,908)			(34,908)
Ending balance (in shares) at Sep. 30, 2023		69,827,000
Ending balance at Sep. 30, 2023	$ 91,506	$ 6	$ 581,838	$ (490,338)

Condensed Consolidated Statem_4

Condensed Consolidated Statements of Stockholders' Equity (Unaudited) (Parenthetical) $ in Thousands	9 Months Ended
	Sep. 30, 2023 USD ($)
Statement of Stockholders' Equity [Abstract]
Costs incurred in connection with offering	$ 721

Condensed Consolidated Statem_5

Condensed Consolidated Statements of Cash Flows (Unaudited) $ in Thousands	3 Months Ended	9 Months Ended
	Sep. 30, 2023 USD ($)	Sep. 30, 2023 USD ($)	Sep. 30, 2022 USD ($)
Operating activities:
Net loss	$ (34,908)	$ (69,048)	$ (20,988)
Adjustments to reconcile net loss to net cash provided by (used in) operating activities:
Depreciation	1,357	4,302	3,961
Amortization of right-of-use assets		3,647	3,618
Stock-based compensation	2,283	7,808	11,600
Provision (recovery) for credit losses		0	(307)
Equity securities earned from research and development activities ($0 and $1,245 from a related party)		187	1,245
Unrealized gain on non-marketable securities		0	208
Asset impairment and other charges	9,984	9,984	0
Impairment of investment in non-marketable equity securities	3,900	3,875	0
Other non-cash items		(3)	(29)
Changes in operating assets and liabilities:
Financial assets		21,580	8,184
Inventories		(276)	(463)
Prepaid expenses and other assets		(252)	429
Accounts payable		(105)	(351)
Accrued compensation and other accrued liabilities		(7,269)	2,279
Other long-term liabilities		(4,384)	(3,863)
Deferred revenue		(11,273)	3,750
Net cash provided by (used in) operating activities		(41,601)	6,367
Investing activities:
Purchase of property and equipment		(4,798)	(8,340)
Proceeds from sale of property and equipment		27	29
Investment in non-marketable securities		(1,191)	(5,300)
Net cash used in investing activities		(5,962)	(13,611)
Financing activities:
Proceeds from exercises of stock options		422	612
Proceeds from issuance of common stock in connection with public offering		8,652	0
Costs incurred in connection with issuance of common stock at public offering		(503)	(42)
Taxes paid related to net share settlement of equity awards		(404)	(1,484)
Net cash provided by (used in) financing activities		8,167	(914)
Net decrease in cash, cash equivalents and restricted cash		(39,396)	(8,158)
Cash, cash equivalents and restricted cash at the beginning of the period		116,026	118,895
Cash, cash equivalents and restricted cash at the end of the period	76,630	76,630	110,737
Supplemental disclosure of cash flow information:
Interest paid		28	22
Income taxes paid		193	100
Supplemental non-cash investing and financing activities:
Capital expenditures incurred but not yet paid		159	128
Cash reconciliation:
Cash and cash equivalents	74,577	74,577	108,689
Restricted cash, current and non-current	2,053	2,053	2,048
Total cash, cash equivalents and restricted cash	$ 76,630	$ 76,630	$ 110,737

Condensed Consolidated Statem_6

Condensed Consolidated Statements of Cash Flows (Unaudited) (Parenthetical) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022
Equity securities earned from research and development activities	$ (187)	$ (1,245)
Related Party
Equity securities earned from research and development activities	$ 0	$ (1,245)

Description of Business

Description of Business	9 Months Ended
	Sep. 30, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Description of Business	Description of Business In these notes to the unaudited condensed consolidated financial statements, the “Company,” “we,” “us,” and “our” refers to Codexis, Inc. and its subsidiaries on a consolidated basis. We discover, develop, enhance, and commercialize novel, high performance enzymes and other classes of proteins leveraging our proprietary CodeEvolver ® directed evolution platform. As of September 30, 2023, we reported our financial results based on two reportable segments: Performance Enzymes and Novel Biotherapeutics. Our Performance Enzymes business consists primarily of two focus areas: i) biocatalysts for the enzymatic manufacturing of pharmaceuticals and ii) enzymes for life science applications, including genomic sequencing and nucleic acid synthesis. Our Novel Biotherapeutics business includes product candidates in clinical and preclinical development. The segment information aligns with how the chief operating decision maker ( “ CODM ” ), who is our Chief Executive Officer ( “ CEO ” ), reviews and manages the business. In July 2023, we announced a restructuring of our business and that we are discontinuing investment in certain development programs, primarily in Novel Biotherapeutics.

Basis of Presentation and Summa

Basis of Presentation and Summary of Significant Accounting Policies	9 Months Ended
	Sep. 30, 2023
Accounting Policies [Abstract]
Basis of Presentation and Summary of Significant Accounting Policies	Basis of Presentation and Summary of Significant Accounting Policies Basis of Presentation and Principles of Consolidation The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America ("GAAP") and the applicable rules and regulations of the Securities and Exchange Commission ("SEC") for interim financial information but does not include all the information and notes required by GAAP for complete financial statements. These interim unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto contained in our Annual Report on Form 10-K for the year ended December 31, 2022. The condensed consolidated balance sheet at December 31, 2022 has been derived from the audited consolidated financial statements at that date, but does not include all disclosures, including notes, required by GAAP for complete financial statements. The significant accounting policies used in preparation of the unaudited condensed consolidated financial statements for the three and nine months ended September 30, 2023 and 2022, are consistent with those discussed in Note 2 to the audited consolidated financial statements in the Company’s 2022 Annual Report on Form 10-K and are updated below as necessary. There have been no significant changes in our significant accounting policies or critical accounting estimates since December 31, 2022. The unaudited condensed consolidated financial statements have been prepared on the same basis as the audited consolidated financial statements and, in the opinion of management, reflect all adjustments of a normal recurring nature considered necessary to present fairly our financial position as of September 30, 2023, results of our operations for the three and nine months ended September 30, 2023 and 2022, changes in stockholders' equity for the three and nine months ended September 30, 2023 and 2022, and cash flows for the nine months ended September 30, 2023 and 2022. The interim results are not necessarily indicative of the results for any future interim period or for the entire year. The unaudited condensed consolidated financial statements include the accounts of Codexis, Inc. and its wholly owned subsidiaries. All intercompany balances and transactions have been eliminated in consolidation. Use of Estimates The preparation of our unaudited condensed consolidated financial statements in conformity with GAAP requires us to make estimates, judgments and assumptions that may affect the reported amounts of assets, liabilities, equity, revenues and expenses and related disclosure of contingent assets and liabilities. We regularly assess these estimates which primarily affect revenue recognition, deferred revenue, inventories, valuation of equity investments, valuation of assets held for sale, goodwill arising out of business acquisitions, accrued liabilities, stock awards, and the valuation allowances associated with deferred tax assets. Actual results could differ from those estimates and such differences may be material to the consolidated financial statements. Impairment of Long-Lived Assets We evaluate the carrying values of long-lived assets, which include property and equipment and right-of-use assets, whenever events, changes in business circumstances or our planned use of long-lived assets indicate that their carrying amounts may not be fully recoverable or that their useful lives are no longer appropriate. If these facts and circumstances exist, we assess for recovery by comparing the carrying values of long-lived assets with the future net undiscounted cash flows expected to be generated by the asset. If such assets are considered to be impaired, the impairment to be recognized is measure by the amount by which the carrying amount of the asset exceeds the fair value of the asset. For additional information on the impairment charge recorded in the three and nine months ended September 30, 2023, s ee Note 7, “Balance Sheets Details” and Note 10, “Commitments and Contingencies.” Assets Held For Sale The Company classifies assets as held for sale when the following conditions are met: (i) management has committed to a plan to sell, (ii) the assets are available for immediate sale in their present condition, (iii) the Company has initiated an active program to identify a buyer, (iv) it is probable that a sale will occur within one year, (v) the assets are actively marketed for sale at a reasonable price in relation to their current fair value, and (vi) there is a low likelihood of significant changes to the plan or that the plan will be withdrawn. If all of the criteria are met as of the balance sheet date, the assets are presented separately in the consolidated balance sheet as held for sale at the lower of the carrying amount or fair value less costs to sell. The assets are then no longer depreciated or amortized while classified as held for sale. For additional information, see Note 15, “Assets Held For Sale.” Accounting Pronouncements Recently adopted accounting pronouncements or recently issued accounting pronouncements not yet adopted There were no recent accounting pronouncements or changes in accounting pronouncements during the three and nine months ended September 30, 2023, that are of significance or potential significance to us.

Revenue Recognition

Revenue Recognition	9 Months Ended
	Sep. 30, 2023
Revenue from Contract with Customer [Abstract]
Revenue Recognition	Revenue Recognition Disaggregation of Revenue The following table provides information about disaggregated revenue from contracts with customers into the nature of the products and services, and geographic regions, and includes a reconciliation of the disaggregated revenue with reportable segments. The geographic regions that are tracked are the Americas (United States, Canada, and Latin America), EMEA (Europe, Middle East, and Africa), and APAC (Australia, New Zealand, Southeast Asia, and China). Segment information is as follows (in thousands): Three Months Ended September 30, 2023 Three Months Ended September 30, 2022 Performance Enzymes Novel Biotherapeutics Total Performance Enzymes Novel Biotherapeutics Total Major products and service: Product revenue $ 5,395 $ — $ 5,395 $ 28,042 $ — $ 28,042 Research and development revenue 3,315 567 3,882 3,104 3,324 6,428 Total revenues $ 8,710 $ 567 $ 9,277 $ 31,146 $ 3,324 $ 34,470 Primary geographical markets: Americas $ 4,278 $ — $ 4,278 $ 3,654 $ 1,168 $ 4,822 EMEA 2,624 567 3,191 3,831 2,156 5,987 APAC 1,808 — 1,808 23,661 — 23,661 Total revenues $ 8,710 $ 567 $ 9,277 $ 31,146 $ 3,324 $ 34,470 Nine Months Ended September 30, 2023 Nine Months Ended September 30, 2022 Performance Enzymes Novel Biotherapeutics Total Performance Enzymes Novel Biotherapeutics Total Major products and service: Product revenue $ 24,807 $ — $ 24,807 $ 93,376 $ — $ 93,376 Research and development revenue 12,696 6,079 18,775 7,398 7,441 14,839 Total revenues $ 37,503 $ 6,079 $ 43,582 $ 100,774 $ 7,441 $ 108,215 Primary geographical markets: Americas $ 8,865 $ 1,933 $ 10,798 $ 8,514 $ 3,653 $ 12,167 EMEA 10,484 4,146 14,630 11,017 3,788 14,805 APAC 18,154 — 18,154 81,243 — 81,243 Total revenues $ 37,503 $ 6,079 $ 43,582 $ 100,774 $ 7,441 $ 108,215 Contract Balances The following table presents balances of contract assets, unbilled receivables, contract costs, and contract liabilities (in thousands): September 30, 2023 December 31, 2022 Contract assets $ 1,936 $ 2,116 Unbilled receivables $ 5,661 $ 7,016 Contract costs $ — $ 19 Contract liabilities: deferred revenue $ 19,336 $ 30,609 We had no asset impairment charges related to financial assets in the three and nine months ended September 30, 2023 and 2022. The decrease in contract assets was primarily due to decreases in product revenue from contracts subject to over time revenue recognition. The decrease in unbilled receivables was primari ly due to the timing of billings. T he decrease in deferred revenue was primarily due to timing of recognition of revenue, including the $2.9 million rel ease of prior periods' product revenue deferrals during the second quarter of 2023 due to early termination of the enzyme supply obligations to a customer . We recognized the following revenues (in thousands): Three Months Ended September 30, Nine Months Ended September 30, Revenue recognized in the period for: 2023 2022 2023 2022 Amounts included in contract liabilities at the beginning of the period: Performance obligations satisfied $ 1,303 $ 889 $ 9,111 $ 1,694 Changes in the period: Changes in the estimated transaction price allocated to performance obligations satisfied in prior periods 1,018 495 4,238 365 Performance obligations satisfied from new activities in the period - contract revenue 6,956 33,086 30,233 106,156 Total revenues $ 9,277 $ 34,470 $ 43,582 $ 108,215 Performance Obligations The following table includes estimated revenue expected to be recognized in the future related to performance obligations that are unsatisfied or partially unsatisfied at the end of the reporting periods. The estimated revenue does not include contracts with original durations of one year or less, amounts of variable consideration attributable to royalties, or contract renewals that are unexercised as of September 30, 2023. The balances in the table below are partially based on judgments involved in estimating future orders from customers subject to the exercise of material rights pursuant to respective contracts as of September 30, 2023 (in thousands): Remainder of 2023 2024 2025 2026 and Thereafter Total Product revenue $ 8,446 $ 9,590 $ 140 $ 500 $ 18,676 Research and development revenue 660 — — — 660 Total revenues $ 9,106 $ 9,590 $ 140 $ 500 $ 19,336

Net Loss per Share

Net Loss per Share	9 Months Ended
	Sep. 30, 2023
Earnings Per Share [Abstract]
Net Loss per Share	N et Loss per S hare Basic net loss per share is computed by dividing the net loss by the weighted-average number of shares of common stock outstanding, less restricted stock awards ("RSAs") subject to forfeiture. Diluted net loss per share is computed by dividing net loss by the weighted-average number of shares of common stock shares outstanding, less RSAs subject to forfeiture, plus all additional common shares that would have been outstanding, assuming dilutive potential common stock shares had been issued for other dilutive securities. For all periods presented, diluted and basic net loss per share, are identical since potential common stock shares are excluded from the calculation, as their effect was anti-dilutive. Anti-Dilutive Securities In periods of net loss, the weighted average number of shares outstanding, prior to the application of the treasury stock method, excludes potentially dilutive securities from the computation of diluted net loss per common share because including such shares would have an anti-dilutive effect. The following shares were not considered in the computation of diluted net loss per share because their effect was anti-dilutive (in thousands): Three Months Ended September 30, Nine Months Ended September 30, 2023 2022 2023 2022 Shares issuable under the Equity Incentive Plan 8,873 6,604 8,873 6,604

Investments in Non-Marketable S

Investments in Non-Marketable Securities	9 Months Ended
	Sep. 30, 2023
Investments, Debt and Equity Securities [Abstract]
Investments in Non-Marketable Securities	Investments in Non-Marketable Securities Non-Marketable Equity Securities In March 2023, we purchased an additional 985,545 shares of Series B preferred stock for $0.8 million in Molecular Assemblies, Inc. (“MAI”), a privately held life sciences company . As of September 30, 2023, we held an aggregate of 19,277,914 shares of MAI's Series A and B preferred stock that we have earned or purchased from MAI. See Note 11 “Related Party Transactions” for additional information on our investment in MAI. In March 2022, we entered into a Stock Purchase Agreement with seqWell, Inc. (“seqWell”), a privately held life sciences company, pursuant to which we purchased 1,000,000 shares of seqWell's Series C preferred stock for $5.0 million. In March 2023, we entered into a Master Collaboration Agreement and Research Agreement with seqWell (the “seqWell Agreement”), pursuant to which we are providing research and experimental screening and protein engineering activities in exchange for compensation in the form of additional shares of seqWell's common stock. In addition to our initial equity investment and the shares we have received under the seqWell Agreement, in September 2023, we purchased an additional 88,256 shares of seqWell's Series C-1 preferred stock and 44,128 common stock warrants for $0.4 million. We received 65,982 and 179,897 shares of seqWell's common stock from research and development services with seqWell and we recognized $69 thousand and $187 thousand in research and development revenue from these services during the three and nine months ended September 30, 2023, respectively. We own 207,070 shares of Series B-2 preferred stock of Arzeda Corp. (“Arzeda”), an early-stage computational protein design company. Our non-marketable equity securities are investments in privately held companies without readily determinable market value and primarily relate to our investments in MAI, seqWell and Arzeda. These investments are accounted for under the measurement alternative and are measured at cost minus impairment, if any, plus or minus changes resulting from observable price changes for identical or similar securities of the same issuer. Non-marketable equity securities are measured at fair value on a non-recurring basis and classified within Level 2 in the fair value hierarchy when we estimate the fair value of these investments using the observable transaction price paid by third party investors for the same or similar security of the same issuers. The fair value of non-marketable equity securities are classified within Level 3 when we estimate fair value using unobservable inputs such as when we remeasure due to impairment and we use discount rates, market data of comparable companies, and rights and obligations of the securities the Company holds, among others. We adjust the carrying value of non-marketable equity securities which have been remeasured during the period and recognize resulting gains or losses as a component of other expense, net in the unaudited condensed consolidated statements of operations. For the three months ended September 30, 2023, we recognized an impairment charge of $3.9 million and included this as adjustment to the carrying value of our investments in seqWell and Arzeda. This adjustment, which is presented within other income (expense), net in the condensed consolidated statements of operations, is related to the write-down of the carrying value of our investments in seqWell by $3.0 million and in Arzeda by $0.9 million to its estimated fair values as determined based on valuation methods using the recent transaction price of similar preferred stock securities issued by the investees and adjusted for the rights and obligations of the preferred stock securities the Company holds. For the three months ended September 30, 2022, we recognized a $0.2 million unrealized gain and included as adjustment to the carrying value of our investment in MAI, for the remeasurement of the additional 1,587,049 shares of Series B preferred stock received as milestone payment during the three months ended September 30, 2022 based on the latest observed transaction price of MAI's preferred stock. There was no remeasurement event for our investments in other non-marketable equity securities that occurred during the three and nine months ended September 30, 2023 and 2022. We recognize d no realized gains or losses during the three and nine months ended September 30, 2023 and 2022. The following table presents the carrying value of our non-marketable equity securities (in thousands): September 30, 2023 December 31, 2022 MAI $ 14,671 $ 13,921 seqWell 2,598 5,000 Arzeda 444 1,289 Other investments in non-marketable equity securities 300 300 Total non-marketable equity securities $ 18,013 $ 20,510

Fair Value Measurements

Fair Value Measurements	9 Months Ended
	Sep. 30, 2023
Fair Value Disclosures [Abstract]
Fair Value Measurements	Fair Value Measurements The following tables present the financial instruments that were measured at fair value on a recurring basis within the fair value hierarchy (in thousands): September 30, 2023 Level 1 Level 2 Level 3 Total Money market funds $ 65,585 $ — $ — $ 65,585 December 31, 2022 Level 1 Level 2 Level 3 Total Money market funds $ 77,309 $ — $ — $ 77,309 During the three and nine months ended September 30, 2023 and 2022, we did not recognize any significant credit losses nor other-than-temporary impairment losses on non-marketable securities. The investments in non-marketable securities that have been remeasured due to an observable event or impairment are classified within Level 3 in the fair value hierarchy because we estimate the value based on valuation methods which may include a combination of the observable transaction price at the transaction date and other unobservable inputs including rights and obligations of the investments we hold. For additional information, see Note 5, “Investments in Non-Marketable Securities.” As of September 30, 2023, the Company had classifie d $0.6 million of laboratory equipment, net of accumulated depreciation, that it intends to sell within the next quarter and that meets the held for sale criteria, to assets held for sale in the condensed consolidated balance sheet. The estimated fair values (Level 2 fair value measurements) were determined based on the quoted proceeds from the sale of these assets less costs to sell. For additional information, see Note 15, “Assets Held For Sale.”

Balance Sheets Details

Balance Sheets Details	9 Months Ended
	Sep. 30, 2023
Balance Sheets Details [Abstract]
Balance Sheets Details	Balance Sheets Details Cash Equivalents Cash equivalents as of September 30, 2023 and December 31, 2022, consisted of the following (in thousands): September 30, 2023 December 31, 2022 Adjusted Cost Estimated Fair Value Adjusted Cost Estimated Fair Value Money market funds (1) $ 65,585 $ 65,585 $ 77,309 $ 77,309 (1) Money market funds are classified in cash and cash equivalents on our unaudited condensed consolidated balance sheets. Average contractual maturities (in days) is not applicable. As of September 30, 2023, the total cash and cash equivalents balance of $74.6 million consisted of money market funds of $65.6 million and cash of $9.0 million held with major financial institutions. As of December 31, 2022, the total cash and cash equivalents balance of $114.0 million consisted of money market funds of $77.3 million and cash of $36.7 million held with major financial institutions. Inventories Inventories consisted of the following (in thousands): September 30, 2023 December 31, 2022 Raw materials $ 108 $ 108 Work-in-process — 91 Finished goods 2,197 1,830 Total Inventories $ 2,305 $ 2,029 Inventories are recorded net of reserves of $1.4 million as of September 30, 2023 and December 31, 2022. Property and Equipment, net Property and equipment, net consisted of the following (in thousands): September 30, 2023 December 31, 2022 Laboratory equipment $ 36,376 $ 39,679 Leasehold improvements 11,750 16,633 Computer equipment and software 3,096 3,039 Office equipment and furniture 1,366 1,345 Construction in progress 1,781 1,739 Property and equipment 54,369 62,435 Less: accumulated depreciation and amortization (39,087) (39,821) Property and equipment, net $ 15,282 $ 22,614 During the three and nine months ended September 30, 2023, the Company recorded a n on-cash impairment charge of $4.7 million associated with the San Carlos facility leasehold improvements. For additional information, see Note 10, “Commitments and Contingencies.” As of September 30, 2023, the Company had classi fied $2.1 million of laboratory equipment, net of accumulated depreciation, that it intends to sell within the next quarter and that meets the held for sale criteria, to assets held for sale. The Company determined that the carrying value of the assets held for sale exceeds fair value less costs to sell, which resulted in a write-down o f $1.5 million, presented within the asset impairment and other charges line item in the condensed consolidated statements of operations, for the quarter ended September 30, 2023. As of September 30, 2023, the Company has presented $0.6 million of assets held for sale in the condensed consolidated balance sheet. For additional information, see Note 15, “Assets Held For Sale.” Depreciation expense included in both research and development expenses and selling, general and administrative expenses in the unaudited condensed consolidated statements of operations was as follows (in thousands): Three Months Ended September 30, Nine Months Ended September 30, 2023 2022 2023 2022 Depreciation expense $ 1,357 $ 1,405 $ 4,302 $ 3,961 Goodwill Goodwill Balance at January 1, 2023 $ 3,241 Impairment (778) Balance at September 30, 2023 $ 2,463 Goodwill was allocated to each of the Company's reporting units. In July 2023, we announced a restructuring of our business and that we are discontinuing investment in certain development programs, primarily in Novel Biotherapeutics. As a result of this plan, the Company determined that a triggering event had occurred that required an interim goodwill impairment test during the third quarter of 2023. Based on the results of the impairment evaluation, the Company determined that the goodwill within the Novel Biotherapeutics reporting unit was impaired, which resulted in a non-cash impairment charge of $0.8 million to write off all of the associated goodwill. The impairment charge is recorded within the asset impairment and other charges in the condensed consolidated statements of operation for the three and nine months ended September 30, 2023 . Goodwill had a carrying value of $2.5 million and $3.2 million as of September 30, 2023 and December 31, 2022, respectively. Other Accrued Liabilities Other accrued liabilities consisted of the following (in thousands): September 30, 2023 December 31, 2022 Accrued professional and outside service fees $ 5,149 $ 3,495 Accrued purchases 2,644 10,852 Other 1,003 932 Total other accrued liabilities $ 8,796 $ 15,279

Stock-based Compensation

Stock-based Compensation	9 Months Ended
	Sep. 30, 2023
Share-Based Payment Arrangement [Abstract]
Stock-based Compensation	Stock-based Compensation Equity Incentive Plans In January 2023, our board of directors (the “Board”) approved the 2022 Employment Inducement Award Plan (the “2022 Inducement Plan”) which provides for the grant of non-qualified stock options, restricted stock awards (“RSAs”), restricted stock units (“RSUs”), performance awards, other stock awards and dividend equivalents to eligible employees with respect to an aggregate of up to 2,000,000 shares of our common stock. In June 2023, the 2022 Inducement Plan was terminated upon the approval of an amendment to the Company's 2019 Incentive Award Plan (the “2019 Plan”) at the 2023 annual meeting of the Company's stockholders (the “Annual Meeting”). In 2019, the Board and stockholders approved the 2019 Plan. The 2019 Plan superseded and replaced in its entirety our 2010 Equity Incentive Plan (the “2010 Plan”) which was effective in March 2010, and no further awards will be granted under the 2010 Plan; however, the terms and conditions of the 2010 Plan will continue to govern any outstanding awards thereunder. The 2010 Plan provided for the grant of incentive stock options, non-statutory stock options, RSUs, RSAs, PSUs, PBOs, stock appreciation rights, and stock purchase rights to our employees, non-employee directors and consultants. The 2019 Plan provides for the grant of stock options, including incentive stock options and non-qualified stock options, stock appreciation rights, RSA, RSUs, performance-contingent restricted stock units (“PSUs”), performance based options (“PBOs”), other stock or cash based awards and dividend equivalents to eligible employees and consultants of the Company or any parent or subsidiary, as well as members of the Board. The number of shares of our common stock that were initially available for issuance under the 2019 Plan is equal to the sum of (i) 7,897,144 shares, and (ii) any shares subject to awards granted under the 2010 Plan that were outstanding as of April 22, 2019 and thereafter terminate, expire, lapse or are forfeited. In June 2019, 8.1 million shares authorized for issuance under the 2019 Plan were registered under the Securities Act of 1933, as amended (the “Securities Act”). In April 2023, the Board approved an amendment to the 2019 Plan (the “2019 Amended Plan”) which became effective upon stockholders' approval at the Annual Meeting in June 2023. The 2019 Amended Plan included the (i) increase in the number of shares available by 8,000,000 shares, such that an aggregate of 15,897,144 shares are reserved for issuance under the 2019 Amended Plan and any shares subject to awards granted under the 2010 Plan, and (ii) increase in the number of shares that may be granted as incentive stock options under the 2019 Amended Plan such that an aggregate of 22,000,000 shares of common stock may be granted as incentive stock options under the 2019 Amended Plan. Employee Stock Purchase Plan In April 2023, the Board approved an employee stock purchase plan (the “ESPP”) which became effective upon approval at the Annual Meeting in June 2023 of the Company's stockholders. The ESPP allows eligible employees of the Company to purchase shares of our common stock through payroll deductions over 24-month offering periods. The per share purchase price will be the lower of 85% of the closing trading price per share of our common stock on the first trading date of an offering period in which a participant is enrolled or 85% of the closing trading price per share on the purchase date. Participant purchases are limited to a maximum of $25,000 of fair value of our stock per calendar year. The Company is authorized to grant up to 2,000,000 shares of common stock under the ESPP. As of September 30, 2023, the Company had not issued any shares of common stock nor recognized any stock-based compensation expenses related to the ESPP. Stock Options The option exercise price for incentive stock options must be at least 100% of the fair value of our common stock on the date of grant and the option exercise price for non-statutory stock options is at least 85% of the fair value of our common stock on the date of grant, as determined by the Board. If, at the time of a grant, the optionee directly or by attribution owns stock possessing more than 10% of the total combined voting power of all of our outstanding capital stock, the exercise price for these options must be at least 110% of the fair value of the underlying common stock. Stock options granted to employees generally have a maximum term of ten years and vest over four years from the date of grant, of which 25% vest at the end of one year, and 75% vest monthly over the remaining three years. We may grant options with different vesting terms from time to time. Unless an employee's termination of service is due to disability or death, upon termination of service, any unexercised vested options will be forfeited at the end of three months or the expiration of the option, whichever is earlier. Restricted Stock Units ("RSUs") We also grant employees RSUs, which generally vest over either a three year period with 33% of the shares subject to the RSUs vesting on each yearly anniversary of the vesting commencement date or over a four year period with 25% of the shares subject to the RSU vesting on each yearly anniversary of the vesting commencement date, in each case contingent upon such employee’s continued service on such vesting date. RSUs are generally subject to forfeiture if employment terminates prior to the release of vesting restrictions. We may grant RSUs with different vesting terms from time to time. Performance-contingent Restricted Stock Units ("PSUs") and Performance Based Options ("PBOs") In prior years, the compensation committee of the Board approved grants of PBOs and PSUs to our executives, and solely in respect of non-executive employees, delegated to our CEO the authority to approve grants of PSUs. The PSUs and PBOs vest based upon both the successful achievement of certain corporate operating milestones in specified timelines and continued employment through the applicable vesting date. When the performance goals are deemed to be probable of achievement for these types of awards, recognition of stock-based compensation expense commences. Once the number of shares eligible to vest is determined, those shares vest in two equal installments with 50% vesting upon achievement, as determined by the compensation committee of the Board, and the remaining 50% vesting on the first anniversary of achievement, in each case, subject to the recipient’s continued service through the applicable vesting date. If the performance goals are achieved at the threshold level, the number of shares eligible to vest in respect of the PSUs and PBOs would be equal to half the number of PSUs granted and one-quarter the number of shares underlying the PBOs granted. If the performance goals are achieved at the target level, the number of shares eligible to vest in respect of the PSUs and PBOs would be equal to the number of PSUs granted and half of the shares underlying the PBOs granted. If the performance goals are achieved at the superior level, the number of shares eligible to vest in respect of the PSUs would be equal to two times the number of PSUs granted and equal to the number of PBOs granted. The number of shares issuable upon achievement of the performance goals at the levels between the threshold and target levels for the PSUs and PBOs or between the target level and superior levels for the PSUs would be determined using linear interpolation. Achievement below the threshold level would result in no shares being eligible to vest in respect of the PSUs and PBOs. No PSUs and PBOs were granted during the nine months ended September 30, 2023. In 2022, we awarded PSUs ("2022 PSUs") and PBOs ("2022 PBOs"), each of which commence vesting based upon the achievement of various weighted performance go als, including finance and corporate strategy, performance enzymes and biotherapeutics deliverables, research plans, and organizational development. In the first quarter of 2023, the compensation committee of the Board determined that the 2022 PSUs and 2022 PBOs performance goals had been achieved at 85% and 42.5% of the target level, respectively, and recognized stock-based compensation expenses accordingly. Accordingly, 50% of the shares underlying the 2022 PSUs and PBOs vested in the first quarter of 2023 and 50% of the shares underlying the 2022 PSUs and PBOs will vest in the first quarter of 2024, in each case , subject to the recipient’s continued service on each vesting date. In 2021, we awarded PSUs ("2021 PSUs") and PBOs ("2021 PBOs"), each of which commence vesting based upon the determination by the compensation committee of the Board of the achievement of various weighted performance goals, including total revenues, product revenue, performance enzymes pipeline advancements, biotherapeutics pipeline advancements, organization and infrastructure upgrades, and significant events that can be publicly announced. In the first quarter of 2022, we determined that the 2021 PSUs and 2021 PBOs performance goals had been achieved at 146% and 73% of the target level, respectively, and recognized stock-based compensation expenses accordingly. Accordingly, 50% of the shares underlying the 2021 PSUs and PBOs vested in the first quarter of 2022 and 50% of the shares underlying the 2021 PSUs and PBOs vested in the first quarter of 2023, in each case , subject to the recipient’s continued service on each vesting date. Stock-Based Compensation Expense Stock-based compensation expense is included in the unaudited condensed consolidated statements of operations as follows (in thousands): Three Months Ended September 30, Nine Months Ended September 30, 2023 2022 2023 2022 Cost of product revenue $ 60 $ 124 $ 272 $ 367 Research and development 450 1,045 1,978 3,110 Selling, general and administrative 1,773 3,362 5,558 8,123 Total $ 2,283 $ 4,531 $ 7,808 $ 11,600 The following table presents total stock-based compensation expense by security type included in the unaudited condensed consolidated statements of operations (in thousands): Three Months Ended September 30, Nine Months Ended September 30, 2023 2022 2023 2022 Stock options $ 1,017 $ 1,679 $ 3,035 $ 3,279 RSUs and RSAs 942 1,290 3,441 3,785 PSUs 292 965 1,408 2,279 PBOs 32 597 (76) 2,257 Total $ 2,283 $ 4,531 $ 7,808 $ 11,600 As of September 30, 2023, unrecognized stock-based compensation expense, net of expected forfeitures, was $9.4 million related to unvested stock options, $6.0 million related to unvested RSUs and RSAs, $0.5 million related to unvested PSUs, and $0.1 million related to unvested PBOs based on current estimates of the level of achievement. Stock-based compensation expense for these awards will be recognized through 2027.

Capital Stock

Capital Stock	9 Months Ended
	Sep. 30, 2023
Equity [Abstract]
Capital Stock	Capital Stock Exercise of Options For the nine months ended September 30, 2023 and September 30, 2022, we issued 214,284 and 252,100 shares, respectively, upon option exercises at a weighted-average exercise price of $1.97 and $2.43 per share, respectively, with net cash proceeds of $0.4 million and $0.6 million, respectively. Equity Distribution Agreement In May 2021, we filed a Registration Statement on Form S-3 with the SEC, that automatically became effective upon its filing, under which we may sell common stock, preferred stock, debt securities, warrants, purchase contracts, and units from time to time in one or more offerings. On February 27, 2023, we filed a post-effective amendment to that Registration on Form S-3. Pursuant to that post-effective amendment, we registered an aggregate $200.0 million of securities. In May 2021, we entered into an Equity Distribution Agreement ("EDA") with Piper Sandler & Co ("PSC"), under which PSC, as our exclusive agent, at our discretion and at such times that we may determine from time to time, may sell over a three-year period from the execution of the EDA up to a maximum of $50.0 million of shares of our common stock. Under the terms of the EDA, PSC may sell the shares at market prices by any method that is deemed to be an "at the market offering" as defined in Rule 415 under the Securities Act. We are not required to sell any shares at any time during the term of the EDA. The EDA will terminate upon the earlier of: (i) the issuance and sale of all shares through PSC on the terms and conditions of the EDA, or (ii) the termination of the EDA in accordance with its terms. Either party may terminate the EDA at any time upon written notification to the other party in accordance with the EDA, and upon such notification, the offering will terminate. Under no circumstances shall any shares be sold pursuant to the EDA after the date which is three years after the registration statement is first declared effective by the SEC. We agreed to pay PSC a commission of 3% of the gross sales price of any shares sold pursuant to the EDA. With the exception of certain expenses, we will pay PSC up to 8% of the gross sales price of the shares sold pursuant to the EDA for a combined amount of commission and reimbursement of PSC's expenses and fees. No shares of our common stock were issued and sold under the EDA during the three months ended September 30, 2023. During the nine months ended September 30, 2023, 3,079,421 shares of our common stock were issued and sold pursuant to the EDA. During the nine months ended September 30, 2023, we received gross proceeds of $8.7 million or $7.9 million in net proceeds after PSC's commissions and direct offering expenses of $0.7 million. As of September 30, 2023, $41.3 million of shares remained available for sale under the EDA. During the three and nine months ended September 30, 2022, no shares of our common stock were issued pursuant to the EDA.

Commitments and Contingencies

Commitments and Contingencies	9 Months Ended
	Sep. 30, 2023
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Commitments and Contingencies Operating Leases Our headquarters are located in Redwood City, California, where we occupy approximately 77,300 square feet of office and laboratory space in multiple buildings within the same business park operated by Metropolitan Life Insurance Company ("MetLife"). Our lease agreement with MetLife ("RWC Lease") includes approximately 28,200 square feet of space located at 200 and 220 Penobscot Drive, Redwood City, California (the “200/220 Penobscot Space”) and approximately 37,900 square feet of space located at 400 Penobscot Drive, Redwood City, California (the “400 Penobscot Space”) (the 200/220 Penobscot Space and the 400 Penobscot Space are collectively referred to as the “Penobscot Space”), and approximately 11,200 square feet of space located at 501 Chesapeake Drive, Redwood City, California (the “501 Chesapeake Space”). We entered into the initial lease with MetLife for our facilities in Redwood City in 2004 and the RWC Lease has been amended multiple times since then to adjust the leased space and terms of the Lease. In February 2019, we entered into an Eighth Amendment to the Lease (the “Eighth Amendment”) with MetLife with respect to the Penobscot Space and the 501 Chesapeake Space to extend the term of the Lease for additional periods. Pursuant to the Eighth Amendment, the term of the lease of the Penobscot Space has been extended through May 2027. The lease term for the 501 Chesapeake Space has been extended to May 2029. We have one (1) option to extend the term of the lease for the Penobscot Space for five (5) years, and one (1) separate option to extend the term of the lease for the 501 Chesapeake Space for five (5) years. Pursuant to the terms of the RWC Lease, we exercised our right to deliver a letter of credit in lieu of a security deposit. The letter of credit is collateralized by deposit balances held by the bank in the amount of $1.1 million as of September 30, 2023 and December 31, 2022, and are recorded as non-current restricted cash on the unaudited condensed consolidated balance sheets. In January 2021, we entered into a lease agreement with ARE-San Francisco No. 63, LLC ("ARE") to lease a portion of a facility consisting of approximately 36,593 rentable square feet in San Carlos, California to serve as additional office and research and development laboratory space (the "San Carlos Space"). The lease has a 10-year term from the lease commencement date of November 30, 2021 with one option to extend the term for an additional period of 5 years. In July 2023, we announced our plan to consolidate operations from our San Carlos facility to our headquarters in Redwood City. On September 1, 2023, the Company entered into an Assignment and Assumption of Lease (the “Assignment Agreement”) with Vaxcyte, Inc. (“Vaxcyte”), pursuant to which the Company agreed to assign to Vaxcyte, and Vaxcyte agreed to assume from the Company, all of the Company’s right, title and interest in, under and to the San Carlos Space and the Lease Agreement, dated as of January 29, 2021. On September 6, 2023, the Company, Vaxcyte and ARE entered into a Consent to Assignment and First Amendment (the “Consent”) pursuant to which ARE consented to the Assignment Agreement and the assignment by the Company and the assumption by Vaxcyte of the Company’s interest as tenant in the lease and agreed to release the Company from all of its obligations under the lease that accrue from and after the assignment, and following the assignment, to return the Company's security deposit of approximately $0.5 million provided to ARE in the form of a letter of credit. Under the Assignment Agreement, the Company will prepay to ARE (i) the base rent, as defined in the lease agreement, with respect to the three-month period commencing on the date of the assignment and (ii) certain amounts payable to ARE in connection with tenant improvements completed by ARE pursuant to the lease, which a mounted to $3.1 million . In connection with the Consent, ARE agreed that neither the Company nor Vaxcyte will be required to remove any existing alterations or improvements to the San Carlos Space. The effective date of the assignment was October 1, 2023, which under the terms of the Assignment Agreement was the earlier of (i) the date Vaxcyte occupies the San Carlos Space for the operation of business or (ii) the date the Company vacated and decommissioned the San Carlos Space and certain other customary conditions were satisfied. We have provided ARE with a $0.5 million security deposit in the form of a letter of credit which we expected to be released in the fourth quarter of 2023 following the effectiveness of the lease assignment in October 1, 2023 and which is recorded as current restricted cash on the condensed consolidated balance sheet. As a result of the Assignment Agreement, the Company remeasured the lease obligation for the San Carlos Space as $3.1 million, or the present value of the remaining lease payments, which consist of the remaining rent through the effectiveness of the lease assignment and certain amounts payable to ARE pursuant to the Assignment Agreement, and wrote off the remaining lease liability of $19.6 million and the corresponding right of use asset balance. Simultaneously, the Company determined that indicators of impairment existed because the lease assignment will impact the utilization of the related right of use assets and leasehold improvements in the San Carlos Space, and therefore performed a recoverability test by estimating future undiscounted net cash flows expected to be generated from the use of these assets. As there were no substantial future cash inflows associated with these assets, the carrying values of these assets were deemed unrecoverable. As a result, the Company recognized a non-cash impairment charge of $7.7 million, of which $4.7 million is related to leasehold improvements and $3.0 million for the right of use assets, presented within the asset impairment and other charges line item in the condensed consolidated statements of operations, for the three and nine months ended September 30, 2023. The tables below tables below show the balance of right-of-use assets and lease obligations as of January 1, 2023 and the balance as of September 30, 2023, including the changes during the period (in thousands): Right-of-use Assets - Operating Lease, net Right-of-use assets - Operating leases, net, at January 1, 2023 $ 39,263 Amortization of right-of-use assets (3,647) Additions 898 Remeasurement due to lease modification (19,622) Impairment (2,997) Right-of-use assets - Operating leases, net, at September 30, 2023 $ 13,895 Lease Obligations - Operating Leases Lease obligations - Operating leases, net, at January 1, 2023 $ 43,638 Lease payments (5,668) Interest accretion 1,631 Remeasurement due to lease modification (19,622) Lease obligations - Operating leases, net, at September 30, 2023 $ 19,979 We are required to restore certain areas of the Redwood City facility that we are renting to its original form. We are expensing the asset retirement obligation over the term of the Redwood City lease. We review the estimated obligation each reporting period and make adjustments if our estimates change. We recorded asset retirement obligations of $0.3 million and $0.5 million as of September 30, 2023 and December 31, 2022, respectively, which are included in other liabilities on the unaudited condensed consolidated balance sheets. Accretion expense related to our asset retirement obligations was nominal in the three and nine months ended September 30, 2023 and 2022. Lease and other information Lease costs, amounts included in measurement of lease obligations and other information related to non-cancellable operating leases and finance leases were as follows (in thousands): Three Months Ended September 30, Nine Months Ended September 30, 2023 2022 2023 2022 Finance lease costs $ — $ — $ — $ 18 Operating lease costs 1,618 1,831 5,278 5,491 Short-term lease costs (1) — — — 40 Total lease costs (2) $ 1,618 $ 1,831 $ 5,278 $ 5,549 (1) Short-term lease costs on leases with terms of over one month and less than one year. (2) The Company had no variable lease costs. Other information: Operating Leases Weighted-average remaining lease term (in years) 3.4 years Weighted-average discount rate 6.7 % Nine Months Ended September 30, Cash paid (in thousands): 2023 2022 Operating cash flows from operating leases $ 5,668 $ 4,658 As of September 30, 2023, our maturity analysis of annual undiscounted cash flows of the non-cancellable operating leases were as follows (in thousands): Years Ending December 31, Operating Leases 2023 (remaining 3 months) $ 4,229 2024 4,727 2025 4,868 2026 5,014 2027 2,533 Thereafter 1,078 Total minimum lease payments 22,449 Less: imputed interest 2,470 Lease obligations $ 19,979 Reconciliation of operating lease liabilities as shown within the unaudited condensed consolidated balance sheets: Current portion of lease obligations - Operating leases $ 6,764 Long-term lease obligations - Operating leases 13,215 Total operating lease liabilities $ 19,979 Other Commitments We enter into supply and service arrangements in the normal course of business. Supply arrangements are primarily for fixed-price manufacture and supply. Service agreements are primarily for the development of manufacturing processes and certain studies. Commitments under service agreements are subject to cancellation at our discretion which may require payment of certain cancellation fees. The timing of completion of service arrangements is subject to variability in estimates of the time required to complete the work. The following table provides quantitative data regarding our other commitments. Future minimum payments reflect amounts that we expect to pay including potential obligations under services agreements subject to risk of cancellation by us (in thousands): Payments Due by Period Total 2023 (Remaining 3 Months) 2024 and Thereafter Facility maintenance agreement $ 1,084 $ 1,039 $ 45 Credit Facility In June 30, 2017, we entered into a credit facility (the “Credit Facility”) with Western Alliance Bank consisting of term loans (“Term Debt”) up to $10.0 million, and advances (“Advances”) under a revolving line of credit ("Revolving Line of Credit") up to $5.0 million with an accounts receivable borrowing base of 80% of eligible accounts receivable. The right to take draws on the Term Debt expired on December 31, 2022. In March 2023, we terminated the Credit Facility with Western Alliance Bank. Legal Proceedings We may be involved in legal actions in the ordinary course of business, including inquiries and proceedings concerning business practices and intellectual property infringement, employee relations and other claims. We will recognize a loss contingency in the unaudited condensed consolidated financial statements when it is probable a liability has been incurred and the amount of the loss can be reasonably estimated. We will disclose any loss contingencies that do not meet both conditions if there is a reasonable possibility that a material loss may have been incurred. Gain contingencies are not recorded until they are realized. Indemnifications We are required to recognize a liability for the fair value of any obligations we assume upon the issuance of a guarantee. We have certain agreements with licensors, licensees and collaborators that contain indemnification provisions. In such provisions, we typically agree to indemnify the licensor, licensee and collaborator against certain types of third party claims. The maximum amount of the indemnifications is not limited. We accrue for known indemnification issues when a loss is probable and can be reasonably estimated. There were no accruals for expenses related to indemnification issues for any periods presented.

Related Party Transactions

Related Party Transactions	9 Months Ended
	Sep. 30, 2023
Related Party Transactions [Abstract]
Related Party Transactions	Related Party Transactions Molecular Assemblies, Inc. In June 2020, we entered into a Stock Purchase Agreement with MAI, a privately held life sciences company, pursuant to which we purchased 1,587,050 shares of MAI's Series A preferred stock for $1.0 million. Mr. Nicols, our former President and CEO until August 2022, also joined MAI’s board of directors in June 2020. Concurrently with our initial equity investment, we entered into a Master Collaboration and Research Agreement with MAI (the “MAI Agreement”), pursuant to which performed services utilizing our CodeEvolver ® protein engineering platform technology to improve DNA polymerase enzymes in exchange for compensation in the form of additional shares of MAI's Series A and B preferred stock which are valued based on the observed transaction price of similar securities that MAI issued to third parties. We completed the R&D service with MAI pursuant to the MAI Agreement during the first quarter of 2022. In addition to our initial equity investment and the shares we have received under the MAI Agreement, in April 2021, we purchased an additional 1,000,000 shares of MAI's Series A preferred stock for $0.6 million and in September 2021, we purchased 9,198,423 shares of MAI's Series B preferred stock for $7.0 million. Revenues recognized from transactions with MAI in the three and nine months ended September 30, 2023, and subsequent to the related party period which ended in August 2022, are included in the condensed consolidated statement of operations. We recognized $1.0 million and $1.2 million in research and development revenue from transactions with MAI in the three and nine months ended September 30, 2022, respectively, and we recognized $0.2 million and $0.4 million in product revenue from transactions with MAI in the three and nine months ended September 30, 2022, respectively, during the related party period

Segment, Geographical and Other

Segment, Geographical and Other Revenue Information	9 Months Ended
	Sep. 30, 2023
Segment Reporting [Abstract]
Segment, Geographical and Other Revenue Information	Segment, Geographical and Other Revenue Information Segment Information As of September 30, 2023, we managed our business as two b usiness segments: Performance Enzymes and Novel Biotherapeutics. Our business segments are primarily based on our organizational structure and our operating results as used by our CODM in assessing performance and allocating resources for the Company. In July 2023, we announced a restructuring of our business and that we are discontinuing investment in certain development programs, primarily in Novel Biotherapeutics. We report corporate-related expenses such as legal, accounting, information technology, and other costs that are not otherwise included in our reportable business segments as "corporate costs." All items not included in income (loss) from operations are excluded from the business segments. We manage our assets on a total company basis, not by business segment, as the majority of our operating assets are shared or commingled. Our CODM does not review asset information by business segment in assessing performance or allocating resources, and accordingly, we do not report asset information by business segment. All of our long lived assets are located in the United States. Factors considered in historically determining the two re portable segments of the Company include the nature of business activities, the management structure directly accountable to our CODM for operating and administrative activities, availability of discrete financial information and information presented to the Board of Directors. Our CODM regularly reviews our segments and the approach provided by management for performance evaluation and resource allocation. Operating expenses that directly support the segment activity are allocated based on segment headcount, revenue contribution or activity of the business units within the segments, based on the corporate activity type provided to the segment. The expense allocation excludes certain corporate costs that are separately managed from the segments. This provides the CODM with more meaningful segment profitability reporting to support operating decisions and allocate resources. The following table provides financial information by our reportable business segments along with a reconciliation to consolidated loss before income taxes (in thousands): Three Months Ended September 30, 2023 Three Months Ended September 30, 2022 Performance Enzymes Novel Biotherapeutics Total Performance Enzymes Novel Biotherapeutics Total Revenues: Product revenue $ 5,395 $ — $ 5,395 $ 28,042 $ — $ 28,042 Research and development revenue 3,315 567 3,882 3,104 3,324 6,428 Total revenues 8,710 567 9,277 31,146 3,324 34,470 Costs and operating expenses: Cost of product revenue 2,249 — 2,249 9,786 — 9,786 Research and development (1) 8,146 4,377 12,523 6,782 13,855 20,637 Selling, general and administrative (1) 1,748 386 2,134 3,791 888 4,679 Restructuring charges 1,182 1,217 2,399 — — — Asset impairment and other charges (2) — 778 778 — — — Total segment costs and operating expenses 13,325 6,758 20,083 20,359 14,743 35,102 Income (loss) from operations $ (4,615) $ (6,191) (10,806) $ 10,787 $ (11,419) (632) Corporate costs (3) (22,736) (7,947) Unallocated depreciation and amortization (1,357) (1,405) Loss before income taxes $ (34,899) $ (9,984) Nine Months Ended September 30, 2023 Nine Months Ended September 30, 2022 Performance Enzymes Novel Biotherapeutics Total Performance Enzymes Novel Biotherapeutics Total Revenues: Product revenue $ 24,807 $ — $ 24,807 $ 93,376 $ — $ 93,376 Research and development revenue 12,696 6,079 18,775 7,398 7,441 14,839 Total revenues 37,503 6,079 43,582 100,774 7,441 108,215 Costs and operating expenses: Cost of product revenue 9,947 — 9,947 29,577 — 29,577 Research and development (1) 24,100 19,929 44,029 19,833 37,279 57,112 Selling, general and administrative (1) 6,578 1,528 8,106 11,208 2,288 13,496 Restructuring charges 1,182 1,362 2,544 — — — Asset impairment and other charges (2) — 778 778 — — — Total segment costs and operating expenses 41,807 23,597 65,404 60,618 39,567 100,185 Income (loss) from operations $ (4,304) $ (17,518) (21,822) $ 40,156 $ (32,126) 8,030 Corporate costs (3) (42,890) (24,940) Unallocated depreciation and amortization (4,302) (3,953) Loss before income taxes $ (69,014) $ (20,863) (1) Research and development expenses and selling, general and administrative expenses exclude depreciation and amortization of finance leases. (2) Impairment charge of $0.8 million is related to the goodwill allocated to the Novel Biotherapeutics segment. (3) Corporate costs include unallocated selling, general and administrative expenses, unallocated asset impairment and restructuring charges, interest income, and other income (expense), net. The following table provides stock-based compensation expense in cluded in loss from operations (in thousands): Three Months Ended September 30, 2023 2022 Performance Enzymes Novel Biotherapeutics Corporate cost Total Performance Enzymes Novel Biotherapeutics Corporate cost Total Stock-based compensation $ 903 $ (235) $ 1,615 $ 2,283 $ 1,593 $ 414 $ 2,524 $ 4,531 Nine Months Ended September 30, 2023 2022 Performance Enzymes Novel Biotherapeutics Corporate cost Total Performance Enzymes Novel Biotherapeutics Corporate cost Total Stock-based compensation $ 2,861 $ 98 $ 4,849 $ 7,808 $ 4,776 $ 1,182 $ 5,642 $ 11,600 Significant Customers Customers that each accounted for 10% or more of our total revenues were as follows: Percentage of Total Revenues for the Three Months Ended September 30, Nine Months Ended September 30, 2023 2022 2023 2022 Customer A 20 % * * * Customer B * 39 % 15 % 54 % Customer C * 13 % * * Customer D * * 10 % * Customer E * * 10 % * * Percentage was less than 10% Customers that each accounted for 10% or more of accounts receivable balances as of the periods presented as follows: Percentage of Accounts Receivables as of September 30, 2023 December 31, 2022 Customer B * 53 % Customer D 15 % * Customer E * 10 % Customer F 38 % * Customer G 17 % * * Percentage was less than 10% Geographical Information Geographic revenues are identified by the location of the customer and consist of the following (in thousands): Three Months Ended September 30, Nine Months Ended September 30, 2023 2022 2023 2022 Revenues Americas $ 4,278 $ 4,822 $ 10,798 $ 12,167 EMEA 3,191 5,987 14,630 14,805 APAC 1,808 23,661 18,154 81,243 Total revenues $ 9,277 $ 34,470 $ 43,582 $ 108,215 Identifiable long-lived assets by location was as follows (in thousands): September 30, 2023 December 31, 2022 United States $ 29,177 $ 61,877 Identifiable goodwill by reporting unit was as follows (in thousands): Performance Enzymes Novel Biotherapeutics Total Goodwill at January 1, 2023 $ 2,463 $ 778 $ 3,241 Impairment — (778) (778) Goodwill at September 30, 2023 $ 2,463 $ — $ 2,463 For additional information on the goodwill impairment, see Note 7, “Balance Sheet Details.”

Allowance for Credit Losses

Allowance for Credit Losses	9 Months Ended
	Sep. 30, 2023
Receivables [Abstract]
Allowance for Credit Losses	Allowance for Credit Losses The following table summarizes the financial assets allowance for credit losses (in thousands): Three Months Ended September 30, Nine Months Ended September 30, 2023 2022 2023 2022 Balance at beginning of period $ 133 $ 109 $ 163 $ 416 Provision for credit losses — — — — Write-offs — — (30) (257) Adjustment to the existing allowance — — — (50) Balance at end of period $ 133 $ 109 $ 133 $ 109 The following tables summarize accounts receivable by aging category (in thousands): September 30, 2023 Current 31-60 Days 61-90 Days 91 Days and over Total over 31 Days Total balance Accounts receivable $ 6,835 $ 4,690 $ 22 $ 82 $ 4,794 $ 11,629 December 31, 2022 Current 31-60 Days 61-90 Days 91 Days and over Total over 31 Days Total balance Accounts receivable $ 28,896 $ 1,747 $ 469 $ 792 $ 3,008 $ 31,904

Restructuring Charges

Restructuring Charges	9 Months Ended
	Sep. 30, 2023
Restructuring and Related Activities [Abstract]
Restructuring Charges	Restructuring Charges In July 2023, in alignment with our enhanced strategic focus, we announced a restructuring of our business, including a plan for a workforce reduction of approximately 25%. During the three and nine months ended September 30, 2023, w e recorded a restructuring charge of $3.1 million related to severance and related benefit costs. As of September 30, 2023, we have accrued $1.9 million as a current liability within accrued compensation on our condensed consolidated balance sheets, which is expected to be paid in the fourth quarter of 2023. We do not expect to record any significant future charges related to the restructuring plan. In November 2022, we announced a plan for a workforce reduction of approximately 18% to realign and optimize our workforce requirements in alignment with our refined corporate strategy. The plan was substantially completed in December 2022 and severance costs were paid through the third quarter of 2023. During the three and nine months ended September 30, 2023, we recorded additional restructuring charges of nil and $0.2 million, respectively, related to severance, bonus and other termination benefits in connection with the workforce reduction announced in November 2022. We do not expect to record any future charges related to the restructuring plan initiated in 2022.

Assets Held For Sale

Assets Held For Sale	9 Months Ended
	Sep. 30, 2023
Discontinued Operations and Disposal Groups [Abstract]
Assets Held For Sale	Assets Held For Sale In July 2023, we announced our plan to consolidate operations from our San Carlos facility to our headquarters in Redwood City. As part of this plan, we entered into agreements to sell certain laboratory equipment located in our San Carlos facility through an asset auction and as part of the lease assignment of the San Carlos Space to Vaxcyte (see further discussion at Note 10, “Commitments and Contingencies”). The fixed assets that will be sold as part of this transaction met the assets held for sale criteria and were reclassified to assets held for sale as of September 30, 2023. The Company determined that the carrying value of the assets held for sale exceeds fair value less costs to sell, which resulted in a write-down o f $1.5 million, presented within the asset impairment and other charges line item in the condensed consolidated statements of operations, for the quarter ended September 30, 2023. As of September 30, 2023, the Company has presented $0.6 million of fixed assets expected to be sold during the fourth quarter of 2023 as a current asset under the caption of “assets held for sale” in the accompanying condensed consolidated balance sheets.

Pay vs Performance Disclosure

Pay vs Performance Disclosure - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Pay vs Performance Disclosure
Net loss	$ (34,908)	$ (9,992)	$ (69,048)	$ (20,988)

Insider Trading Arrangements

Insider Trading Arrangements	3 Months Ended
	Sep. 30, 2023
Trading Arrangements, by Individual
Rule 10b5-1 Arrangement Adopted	false
Non-Rule 10b5-1 Arrangement Adopted	false
Rule 10b5-1 Arrangement Terminated	false
Non-Rule 10b5-1 Arrangement Terminated	false

Basis of Presentation and Sum_2

Basis of Presentation and Summary of Significant Accounting Policies (Policies)	9 Months Ended
	Sep. 30, 2023
Accounting Policies [Abstract]
Basis of Presentation and Principles of Consolidation	Basis of Presentation and Principles of Consolidation The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America ("GAAP") and the applicable rules and regulations of the Securities and Exchange Commission ("SEC") for interim financial information but does not include all the information and notes required by GAAP for complete financial statements. These interim unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto contained in our Annual Report on Form 10-K for the year ended December 31, 2022. The condensed consolidated balance sheet at December 31, 2022 has been derived from the audited consolidated financial statements at that date, but does not include all disclosures, including notes, required by GAAP for complete financial statements. The significant accounting policies used in preparation of the unaudited condensed consolidated financial statements for the three and nine months ended September 30, 2023 and 2022, are consistent with those discussed in Note 2 to the audited consolidated financial statements in the Company’s 2022 Annual Report on Form 10-K and are updated below as necessary. There have been no significant changes in our significant accounting policies or critical accounting estimates since December 31, 2022. The unaudited condensed consolidated financial statements have been prepared on the same basis as the audited consolidated financial statements and, in the opinion of management, reflect all adjustments of a normal recurring nature considered necessary to present fairly our financial position as of September 30, 2023, results of our operations for the three and nine months ended September 30, 2023 and 2022, changes in stockholders' equity for the three and nine months ended September 30, 2023 and 2022, and cash flows for the nine months ended September 30, 2023 and 2022. The interim results are not necessarily indicative of the results for any future interim period or for the entire year.
Use of Estimates	Use of Estimates The preparation of our unaudited condensed consolidated financial statements in conformity with GAAP requires us to make estimates, judgments and assumptions that may affect the reported amounts of assets, liabilities, equity, revenues and expenses and related disclosure of contingent assets and liabilities. We regularly assess these estimates which primarily affect revenue recognition, deferred revenue, inventories, valuation of equity investments, valuation of assets held for sale, goodwill arising out of business acquisitions, accrued liabilities, stock awards, and the valuation allowances associated with deferred tax assets. Actual results could differ from those estimates and such differences may be material to the consolidated financial statements.
Accounting Pronouncements	Accounting Pronouncements Recently adopted accounting pronouncements or recently issued accounting pronouncements not yet adopted There were no recent accounting pronouncements or changes in accounting pronouncements during the three and nine months ended September 30, 2023, that are of significance or potential significance to us.
Segment Information	Segment Information As of September 30, 2023, we managed our business as two b usiness segments: Performance Enzymes and Novel Biotherapeutics. Our business segments are primarily based on our organizational structure and our operating results as used by our CODM in assessing performance and allocating resources for the Company. In July 2023, we announced a restructuring of our business and that we are discontinuing investment in certain development programs, primarily in Novel Biotherapeutics. We report corporate-related expenses such as legal, accounting, information technology, and other costs that are not otherwise included in our reportable business segments as "corporate costs." All items not included in income (loss) from operations are excluded from the business segments. We manage our assets on a total company basis, not by business segment, as the majority of our operating assets are shared or commingled. Our CODM does not review asset information by business segment in assessing performance or allocating resources, and accordingly, we do not report asset information by business segment. All of our long lived assets are located in the United States. Factors considered in historically determining the two re portable segments of the Company include the nature of business activities, the management structure directly accountable to our CODM for operating and administrative activities, availability of discrete financial information and information presented to the Board of Directors. Our CODM regularly reviews our segments and the approach provided by management for performance evaluation and resource allocation. Operating expenses that directly support the segment activity are allocated based on segment headcount, revenue contribution or activity of the business units within the segments, based on the corporate activity type provided to the segment. The expense allocation excludes certain corporate costs that are separately managed from the segments. This provides the CODM with more meaningful segment profitability reporting to support operating decisions and allocate resources.
Impairment of Long-Lived Assets	Impairment of Long-Lived Assets We evaluate the carrying values of long-lived assets, which include property and equipment and right-of-use assets, whenever events, changes in business circumstances or our planned use of long-lived assets indicate that their carrying amounts may not be fully recoverable or that their useful lives are no longer appropriate. If these facts and circumstances exist, we assess for recovery by comparing the carrying values of long-lived assets with the future net undiscounted cash flows expected to be generated by the asset. If such assets are considered to be impaired, the impairment to be recognized is measure by the amount by which the carrying amount of the asset exceeds the fair value of the asset. For additional information on the impairment charge recorded in the three and nine months ended September 30, 2023, s ee Note 7, “Balance Sheets Details” and Note 10, “Commitments and Contingencies.”
Assets Held For Sale	Assets Held For Sale The Company classifies assets as held for sale when the following conditions are met: (i) management has committed to a plan to sell, (ii) the assets are available for immediate sale in their present condition, (iii) the Company has initiated an active program to identify a buyer, (iv) it is probable that a sale will occur within one year, (v) the assets are actively marketed for sale at a reasonable price in relation to their current fair value, and (vi) there is a low likelihood of significant changes to the plan or that the plan will be withdrawn. If all of the criteria are met as of the balance sheet date, the assets are presented separately in the consolidated balance sheet as held for sale at the lower of the carrying amount or fair value less costs to sell. The assets are then no longer depreciated or amortized while classified as held for sale. For additional information, see Note 15, “Assets Held For Sale.”

Revenue Recognition (Tables)

Revenue Recognition (Tables)	9 Months Ended
	Sep. 30, 2023
Revenue from Contract with Customer [Abstract]
Disaggregation of Revenue	Segment information is as follows (in thousands): Three Months Ended September 30, 2023 Three Months Ended September 30, 2022 Performance Enzymes Novel Biotherapeutics Total Performance Enzymes Novel Biotherapeutics Total Major products and service: Product revenue $ 5,395 $ — $ 5,395 $ 28,042 $ — $ 28,042 Research and development revenue 3,315 567 3,882 3,104 3,324 6,428 Total revenues $ 8,710 $ 567 $ 9,277 $ 31,146 $ 3,324 $ 34,470 Primary geographical markets: Americas $ 4,278 $ — $ 4,278 $ 3,654 $ 1,168 $ 4,822 EMEA 2,624 567 3,191 3,831 2,156 5,987 APAC 1,808 — 1,808 23,661 — 23,661 Total revenues $ 8,710 $ 567 $ 9,277 $ 31,146 $ 3,324 $ 34,470 Nine Months Ended September 30, 2023 Nine Months Ended September 30, 2022 Performance Enzymes Novel Biotherapeutics Total Performance Enzymes Novel Biotherapeutics Total Major products and service: Product revenue $ 24,807 $ — $ 24,807 $ 93,376 $ — $ 93,376 Research and development revenue 12,696 6,079 18,775 7,398 7,441 14,839 Total revenues $ 37,503 $ 6,079 $ 43,582 $ 100,774 $ 7,441 $ 108,215 Primary geographical markets: Americas $ 8,865 $ 1,933 $ 10,798 $ 8,514 $ 3,653 $ 12,167 EMEA 10,484 4,146 14,630 11,017 3,788 14,805 APAC 18,154 — 18,154 81,243 — 81,243 Total revenues $ 37,503 $ 6,079 $ 43,582 $ 100,774 $ 7,441 $ 108,215
Contract with Customer	The following table presents balances of contract assets, unbilled receivables, contract costs, and contract liabilities (in thousands): September 30, 2023 December 31, 2022 Contract assets $ 1,936 $ 2,116 Unbilled receivables $ 5,661 $ 7,016 Contract costs $ — $ 19 Contract liabilities: deferred revenue $ 19,336 $ 30,609 We recognized the following revenues (in thousands): Three Months Ended September 30, Nine Months Ended September 30, Revenue recognized in the period for: 2023 2022 2023 2022 Amounts included in contract liabilities at the beginning of the period: Performance obligations satisfied $ 1,303 $ 889 $ 9,111 $ 1,694 Changes in the period: Changes in the estimated transaction price allocated to performance obligations satisfied in prior periods 1,018 495 4,238 365 Performance obligations satisfied from new activities in the period - contract revenue 6,956 33,086 30,233 106,156 Total revenues $ 9,277 $ 34,470 $ 43,582 $ 108,215
Performance Obligation, Expected Timing of Satisfaction	The following table includes estimated revenue expected to be recognized in the future related to performance obligations that are unsatisfied or partially unsatisfied at the end of the reporting periods. The estimated revenue does not include contracts with original durations of one year or less, amounts of variable consideration attributable to royalties, or contract renewals that are unexercised as of September 30, 2023. The balances in the table below are partially based on judgments involved in estimating future orders from customers subject to the exercise of material rights pursuant to respective contracts as of September 30, 2023 (in thousands): Remainder of 2023 2024 2025 2026 and Thereafter Total Product revenue $ 8,446 $ 9,590 $ 140 $ 500 $ 18,676 Research and development revenue 660 — — — 660 Total revenues $ 9,106 $ 9,590 $ 140 $ 500 $ 19,336

Net Loss per Share (Tables)

Net Loss per Share (Tables)	9 Months Ended
	Sep. 30, 2023
Earnings Per Share [Abstract]
Shares Not Included in Computation of Diluted Net Loss Per Share	The following shares were not considered in the computation of diluted net loss per share because their effect was anti-dilutive (in thousands): Three Months Ended September 30, Nine Months Ended September 30, 2023 2022 2023 2022 Shares issuable under the Equity Incentive Plan 8,873 6,604 8,873 6,604

Investments in Non-Marketable_2

Investments in Non-Marketable Securities (Tables)	9 Months Ended
	Sep. 30, 2023
Investments, Debt and Equity Securities [Abstract]
Carrying Value of Non-marketable Equity Securities	The following table presents the carrying value of our non-marketable equity securities (in thousands): September 30, 2023 December 31, 2022 MAI $ 14,671 $ 13,921 seqWell 2,598 5,000 Arzeda 444 1,289 Other investments in non-marketable equity securities 300 300 Total non-marketable equity securities $ 18,013 $ 20,510

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	9 Months Ended
	Sep. 30, 2023
Fair Value Disclosures [Abstract]
Summary of Financial Instruments Measured at Fair Value on a Recurring Basis	The following tables present the financial instruments that were measured at fair value on a recurring basis within the fair value hierarchy (in thousands): September 30, 2023 Level 1 Level 2 Level 3 Total Money market funds $ 65,585 $ — $ — $ 65,585 December 31, 2022 Level 1 Level 2 Level 3 Total Money market funds $ 77,309 $ — $ — $ 77,309

Balance Sheets Details (Tables)

Balance Sheets Details (Tables)	9 Months Ended
	Sep. 30, 2023
Balance Sheets Details [Abstract]
Schedule of Cash and Cash Equivalents	Cash equivalents as of September 30, 2023 and December 31, 2022, consisted of the following (in thousands): September 30, 2023 December 31, 2022 Adjusted Cost Estimated Fair Value Adjusted Cost Estimated Fair Value Money market funds (1) $ 65,585 $ 65,585 $ 77,309 $ 77,309 (1) Money market funds are classified in cash and cash equivalents on our unaudited condensed consolidated balance sheets. Average contractual maturities (in days) is not applicable.
Schedule of Inventory Components	Inventories consisted of the following (in thousands): September 30, 2023 December 31, 2022 Raw materials $ 108 $ 108 Work-in-process — 91 Finished goods 2,197 1,830 Total Inventories $ 2,305 $ 2,029
Schedule of Property and Equipment, Net	Property and equipment, net consisted of the following (in thousands): September 30, 2023 December 31, 2022 Laboratory equipment $ 36,376 $ 39,679 Leasehold improvements 11,750 16,633 Computer equipment and software 3,096 3,039 Office equipment and furniture 1,366 1,345 Construction in progress 1,781 1,739 Property and equipment 54,369 62,435 Less: accumulated depreciation and amortization (39,087) (39,821) Property and equipment, net $ 15,282 $ 22,614 Depreciation expense included in both research and development expenses and selling, general and administrative expenses in the unaudited condensed consolidated statements of operations was as follows (in thousands): Three Months Ended September 30, Nine Months Ended September 30, 2023 2022 2023 2022 Depreciation expense $ 1,357 $ 1,405 $ 4,302 $ 3,961
Schedule of Goodwill	Goodwill Goodwill Balance at January 1, 2023 $ 3,241 Impairment (778) Balance at September 30, 2023 $ 2,463
Schedule of Other Accrued Liabilities	Other accrued liabilities consisted of the following (in thousands): September 30, 2023 December 31, 2022 Accrued professional and outside service fees $ 5,149 $ 3,495 Accrued purchases 2,644 10,852 Other 1,003 932 Total other accrued liabilities $ 8,796 $ 15,279

Stock-based Compensation (Table

Stock-based Compensation (Tables)	9 Months Ended
	Sep. 30, 2023
Share-Based Payment Arrangement [Abstract]
Schedule of Stock-based Compensation Expense	Stock-based compensation expense is included in the unaudited condensed consolidated statements of operations as follows (in thousands): Three Months Ended September 30, Nine Months Ended September 30, 2023 2022 2023 2022 Cost of product revenue $ 60 $ 124 $ 272 $ 367 Research and development 450 1,045 1,978 3,110 Selling, general and administrative 1,773 3,362 5,558 8,123 Total $ 2,283 $ 4,531 $ 7,808 $ 11,600
Schedule of Stock-based Compensation Expense by Security Types	The following table presents total stock-based compensation expense by security type included in the unaudited condensed consolidated statements of operations (in thousands): Three Months Ended September 30, Nine Months Ended September 30, 2023 2022 2023 2022 Stock options $ 1,017 $ 1,679 $ 3,035 $ 3,279 RSUs and RSAs 942 1,290 3,441 3,785 PSUs 292 965 1,408 2,279 PBOs 32 597 (76) 2,257 Total $ 2,283 $ 4,531 $ 7,808 $ 11,600

Commitments and Contingencies (

Commitments and Contingencies (Tables)	9 Months Ended
	Sep. 30, 2023
Commitments and Contingencies Disclosure [Abstract]
Schedule of Right-of-use Assets and Lease Obligations	The tables below tables below show the balance of right-of-use assets and lease obligations as of January 1, 2023 and the balance as of September 30, 2023, including the changes during the period (in thousands): Right-of-use Assets - Operating Lease, net Right-of-use assets - Operating leases, net, at January 1, 2023 $ 39,263 Amortization of right-of-use assets (3,647) Additions 898 Remeasurement due to lease modification (19,622) Impairment (2,997) Right-of-use assets - Operating leases, net, at September 30, 2023 $ 13,895 Lease Obligations - Operating Leases Lease obligations - Operating leases, net, at January 1, 2023 $ 43,638 Lease payments (5,668) Interest accretion 1,631 Remeasurement due to lease modification (19,622) Lease obligations - Operating leases, net, at September 30, 2023 $ 19,979
Lease Cost	Lease costs, amounts included in measurement of lease obligations and other information related to non-cancellable operating leases and finance leases were as follows (in thousands): Three Months Ended September 30, Nine Months Ended September 30, 2023 2022 2023 2022 Finance lease costs $ — $ — $ — $ 18 Operating lease costs 1,618 1,831 5,278 5,491 Short-term lease costs (1) — — — 40 Total lease costs (2) $ 1,618 $ 1,831 $ 5,278 $ 5,549 (1) Short-term lease costs on leases with terms of over one month and less than one year. (2) The Company had no variable lease costs. Other information: Operating Leases Weighted-average remaining lease term (in years) 3.4 years Weighted-average discount rate 6.7 % Nine Months Ended September 30, Cash paid (in thousands): 2023 2022 Operating cash flows from operating leases $ 5,668 $ 4,658
Operating Lease Maturity	As of September 30, 2023, our maturity analysis of annual undiscounted cash flows of the non-cancellable operating leases were as follows (in thousands): Years Ending December 31, Operating Leases 2023 (remaining 3 months) $ 4,229 2024 4,727 2025 4,868 2026 5,014 2027 2,533 Thereafter 1,078 Total minimum lease payments 22,449 Less: imputed interest 2,470 Lease obligations $ 19,979 Reconciliation of operating lease liabilities as shown within the unaudited condensed consolidated balance sheets: Current portion of lease obligations - Operating leases $ 6,764 Long-term lease obligations - Operating leases 13,215 Total operating lease liabilities $ 19,979
Schedule of Supply and Service Commitments	The following table provides quantitative data regarding our other commitments. Future minimum payments reflect amounts that we expect to pay including potential obligations under services agreements subject to risk of cancellation by us (in thousands): Payments Due by Period Total 2023 (Remaining 3 Months) 2024 and Thereafter Facility maintenance agreement $ 1,084 $ 1,039 $ 45

Segment, Geographical and Oth_2

Segment, Geographical and Other Revenue Information (Tables)	9 Months Ended
	Sep. 30, 2023
Segment Reporting [Abstract]
Schedule of Segment Reporting	The following table provides financial information by our reportable business segments along with a reconciliation to consolidated loss before income taxes (in thousands): Three Months Ended September 30, 2023 Three Months Ended September 30, 2022 Performance Enzymes Novel Biotherapeutics Total Performance Enzymes Novel Biotherapeutics Total Revenues: Product revenue $ 5,395 $ — $ 5,395 $ 28,042 $ — $ 28,042 Research and development revenue 3,315 567 3,882 3,104 3,324 6,428 Total revenues 8,710 567 9,277 31,146 3,324 34,470 Costs and operating expenses: Cost of product revenue 2,249 — 2,249 9,786 — 9,786 Research and development (1) 8,146 4,377 12,523 6,782 13,855 20,637 Selling, general and administrative (1) 1,748 386 2,134 3,791 888 4,679 Restructuring charges 1,182 1,217 2,399 — — — Asset impairment and other charges (2) — 778 778 — — — Total segment costs and operating expenses 13,325 6,758 20,083 20,359 14,743 35,102 Income (loss) from operations $ (4,615) $ (6,191) (10,806) $ 10,787 $ (11,419) (632) Corporate costs (3) (22,736) (7,947) Unallocated depreciation and amortization (1,357) (1,405) Loss before income taxes $ (34,899) $ (9,984) Nine Months Ended September 30, 2023 Nine Months Ended September 30, 2022 Performance Enzymes Novel Biotherapeutics Total Performance Enzymes Novel Biotherapeutics Total Revenues: Product revenue $ 24,807 $ — $ 24,807 $ 93,376 $ — $ 93,376 Research and development revenue 12,696 6,079 18,775 7,398 7,441 14,839 Total revenues 37,503 6,079 43,582 100,774 7,441 108,215 Costs and operating expenses: Cost of product revenue 9,947 — 9,947 29,577 — 29,577 Research and development (1) 24,100 19,929 44,029 19,833 37,279 57,112 Selling, general and administrative (1) 6,578 1,528 8,106 11,208 2,288 13,496 Restructuring charges 1,182 1,362 2,544 — — — Asset impairment and other charges (2) — 778 778 — — — Total segment costs and operating expenses 41,807 23,597 65,404 60,618 39,567 100,185 Income (loss) from operations $ (4,304) $ (17,518) (21,822) $ 40,156 $ (32,126) 8,030 Corporate costs (3) (42,890) (24,940) Unallocated depreciation and amortization (4,302) (3,953) Loss before income taxes $ (69,014) $ (20,863) (1) Research and development expenses and selling, general and administrative expenses exclude depreciation and amortization of finance leases. (2) Impairment charge of $0.8 million is related to the goodwill allocated to the Novel Biotherapeutics segment. (3) Corporate costs include unallocated selling, general and administrative expenses, unallocated asset impairment and restructuring charges, interest income, and other income (expense), net. The following table provides stock-based compensation expense in cluded in loss from operations (in thousands): Three Months Ended September 30, 2023 2022 Performance Enzymes Novel Biotherapeutics Corporate cost Total Performance Enzymes Novel Biotherapeutics Corporate cost Total Stock-based compensation $ 903 $ (235) $ 1,615 $ 2,283 $ 1,593 $ 414 $ 2,524 $ 4,531 Nine Months Ended September 30, 2023 2022 Performance Enzymes Novel Biotherapeutics Corporate cost Total Performance Enzymes Novel Biotherapeutics Corporate cost Total Stock-based compensation $ 2,861 $ 98 $ 4,849 $ 7,808 $ 4,776 $ 1,182 $ 5,642 $ 11,600
Schedule of Customers that Contributed 10% or More of Total Accounts Receivable	Significant Customers Customers that each accounted for 10% or more of our total revenues were as follows: Percentage of Total Revenues for the Three Months Ended September 30, Nine Months Ended September 30, 2023 2022 2023 2022 Customer A 20 % * * * Customer B * 39 % 15 % 54 % Customer C * 13 % * * Customer D * * 10 % * Customer E * * 10 % * * Percentage was less than 10% Customers that each accounted for 10% or more of accounts receivable balances as of the periods presented as follows: Percentage of Accounts Receivables as of September 30, 2023 December 31, 2022 Customer B * 53 % Customer D 15 % * Customer E * 10 % Customer F 38 % * Customer G 17 % * * Percentage was less than 10%
Schedule of Revenues by Geographical Area	Geographic revenues are identified by the location of the customer and consist of the following (in thousands): Three Months Ended September 30, Nine Months Ended September 30, 2023 2022 2023 2022 Revenues Americas $ 4,278 $ 4,822 $ 10,798 $ 12,167 EMEA 3,191 5,987 14,630 14,805 APAC 1,808 23,661 18,154 81,243 Total revenues $ 9,277 $ 34,470 $ 43,582 $ 108,215
Schedule of Long-Lived Assets by Geographical Area	Identifiable long-lived assets by location was as follows (in thousands): September 30, 2023 December 31, 2022 United States $ 29,177 $ 61,877
Schedule of Intangible Assets and Goodwill	Identifiable goodwill by reporting unit was as follows (in thousands): Performance Enzymes Novel Biotherapeutics Total Goodwill at January 1, 2023 $ 2,463 $ 778 $ 3,241 Impairment — (778) (778) Goodwill at September 30, 2023 $ 2,463 $ — $ 2,463

Allowance for Credit Losses (Ta

Allowance for Credit Losses (Tables)	9 Months Ended
	Sep. 30, 2023
Receivables [Abstract]
Analysis of Allowance for Credit Losses	The following table summarizes the financial assets allowance for credit losses (in thousands): Three Months Ended September 30, Nine Months Ended September 30, 2023 2022 2023 2022 Balance at beginning of period $ 133 $ 109 $ 163 $ 416 Provision for credit losses — — — — Write-offs — — (30) (257) Adjustment to the existing allowance — — — (50) Balance at end of period $ 133 $ 109 $ 133 $ 109
Summary of Accounts Receivable by Aging	The following tables summarize accounts receivable by aging category (in thousands): September 30, 2023 Current 31-60 Days 61-90 Days 91 Days and over Total over 31 Days Total balance Accounts receivable $ 6,835 $ 4,690 $ 22 $ 82 $ 4,794 $ 11,629 December 31, 2022 Current 31-60 Days 61-90 Days 91 Days and over Total over 31 Days Total balance Accounts receivable $ 28,896 $ 1,747 $ 469 $ 792 $ 3,008 $ 31,904

Description of Business (Detail

Description of Business (Details)	9 Months Ended
	Sep. 30, 2023 segment
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Number of reportable segments	2

Revenue Recognition - Disaggreg

Revenue Recognition - Disaggregation of Revenue (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Disaggregation of Revenue [Line Items]
Total revenues	$ 9,277	$ 34,470	$ 43,582	$ 108,215
Americas
Disaggregation of Revenue [Line Items]
Total revenues	4,278	4,822	10,798	12,167
EMEA
Disaggregation of Revenue [Line Items]
Total revenues	3,191	5,987	14,630	14,805
APAC
Disaggregation of Revenue [Line Items]
Total revenues	1,808	23,661	18,154	81,243
Product revenue
Disaggregation of Revenue [Line Items]
Total revenues	5,395	28,042	24,807	93,376
Research and development revenue
Disaggregation of Revenue [Line Items]
Total revenues	3,882	6,428	18,775	14,839
Performance Enzymes
Disaggregation of Revenue [Line Items]
Total revenues	8,710	31,146	37,503	100,774
Performance Enzymes | Americas
Disaggregation of Revenue [Line Items]
Total revenues	4,278	3,654	8,865	8,514
Performance Enzymes | EMEA
Disaggregation of Revenue [Line Items]
Total revenues	2,624	3,831	10,484	11,017
Performance Enzymes | APAC
Disaggregation of Revenue [Line Items]
Total revenues	1,808	23,661	18,154	81,243
Novel Biotherapeutics
Disaggregation of Revenue [Line Items]
Total revenues	567	3,324	6,079	7,441
Novel Biotherapeutics | Americas
Disaggregation of Revenue [Line Items]
Total revenues	0	1,168	1,933	3,653
Novel Biotherapeutics | EMEA
Disaggregation of Revenue [Line Items]
Total revenues	567	2,156	4,146	3,788
Novel Biotherapeutics | APAC
Disaggregation of Revenue [Line Items]
Total revenues	$ 0	$ 0	$ 0	$ 0

Revenue Recognition - Contracts

Revenue Recognition - Contracts with Customer (Details) - USD ($) $ in Thousands	Sep. 30, 2023	Dec. 31, 2022
Revenue from Contract with Customer [Abstract]
Contract assets	$ 1,936	$ 2,116
Unbilled receivables	5,661	7,016
Contract costs	0	19
Contract liabilities: deferred revenue	$ 19,336	$ 30,609

Revenue Recognition - Narrative

Revenue Recognition - Narrative (Details) - USD ($)	3 Months Ended			9 Months Ended
	Sep. 30, 2023	Jun. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Revenue from Contract with Customer [Abstract]
Impairment charges related to contract assets	$ 0		$ 0	$ 0	$ 0
Contract with customer, liability, release, early termination of obligation		$ 2,900,000

Revenue Recognition - Revenue R

Revenue Recognition - Revenue Recognized During Period (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Amounts included in contract liabilities at the beginning of the period:
Performance obligations satisfied	$ 1,303	$ 889	$ 9,111	$ 1,694
Changes in the period:
Changes in the estimated transaction price allocated to performance obligations satisfied in prior periods	1,018	495	4,238	365
Performance obligations satisfied from new activities in the period - contract revenue	6,956	33,086	30,233	106,156
Total revenues	$ 9,277	$ 34,470	$ 43,582	$ 108,215

Revenue Recognition - Performan

Revenue Recognition - Performance Obligation (Details) $ in Thousands	Sep. 30, 2023 USD ($)
Disaggregation of Revenue [Line Items]
Performance obligation	$ 19,336
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2023-10-01
Disaggregation of Revenue [Line Items]
Performance obligation	$ 9,106
Expected timing of satisfaction, period	3 months
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2024-01-01
Disaggregation of Revenue [Line Items]
Performance obligation	$ 9,590
Expected timing of satisfaction, period	1 year
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2025-01-01
Disaggregation of Revenue [Line Items]
Performance obligation	$ 140
Expected timing of satisfaction, period	1 year
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2026-01-01
Disaggregation of Revenue [Line Items]
Performance obligation	$ 500
Expected timing of satisfaction, period
Product revenue
Disaggregation of Revenue [Line Items]
Performance obligation	$ 18,676
Product revenue | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2023-10-01
Disaggregation of Revenue [Line Items]
Performance obligation	$ 8,446
Expected timing of satisfaction, period	3 months
Product revenue | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2024-01-01
Disaggregation of Revenue [Line Items]
Performance obligation	$ 9,590
Expected timing of satisfaction, period	1 year
Product revenue | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2025-01-01
Disaggregation of Revenue [Line Items]
Performance obligation	$ 140
Expected timing of satisfaction, period	1 year
Product revenue | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2026-01-01
Disaggregation of Revenue [Line Items]
Performance obligation	$ 500
Expected timing of satisfaction, period
Research and development revenue
Disaggregation of Revenue [Line Items]
Performance obligation	$ 660
Research and development revenue | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2023-10-01
Disaggregation of Revenue [Line Items]
Performance obligation	$ 660
Expected timing of satisfaction, period	3 months
Research and development revenue | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2024-01-01
Disaggregation of Revenue [Line Items]
Performance obligation	$ 0
Expected timing of satisfaction, period	1 year
Research and development revenue | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2025-01-01
Disaggregation of Revenue [Line Items]
Performance obligation	$ 0
Expected timing of satisfaction, period	1 year
Research and development revenue | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2026-01-01
Disaggregation of Revenue [Line Items]
Performance obligation	$ 0
Expected timing of satisfaction, period

Net Loss per Share - Shares Not

Net Loss per Share - Shares Not Included in Computation of Diluted Net Loss Per Share (Details) - shares shares in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Shares issuable under the Equity Incentive Plan
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total shares excluded as anti-dilutive (shares)	8,873	6,604	8,873	6,604

Investments in Non-Marketable_3

Investments in Non-Marketable Securities - Narrative (Details) - USD ($)	1 Months Ended				3 Months Ended		9 Months Ended
	Mar. 31, 2023	Sep. 30, 2021	Apr. 30, 2021	Jun. 30, 2020	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022	Dec. 31, 2022	Jun. 30, 2022	Mar. 31, 2022
Marketable Securities [Line Items]
Payments to acquire other investments							$ 1,191,000	$ 5,300,000
Total non-marketable equity securities					$ 18,013,000		18,013,000		$ 20,510,000
Total revenues					9,277,000	$ 34,470,000	43,582,000	108,215,000
Impairment of investment in non-marketable equity securities					3,900,000		3,875,000	0
Unrealized or realized gains or losses					0	0	0	0
Research and development revenue
Marketable Securities [Line Items]
Total revenues					3,882,000	6,428,000	18,775,000	$ 14,839,000
seqWell | Research and development revenue
Marketable Securities [Line Items]
Total revenues					$ 69,000		$ 187,000
Common Stock | seqWell
Marketable Securities [Line Items]
Shares issued in exchange for service					65,982		179,897
seqWell
Marketable Securities [Line Items]
Non-marketable equity securities purchased (in shares)											1,000,000
Total non-marketable equity securities					$ 2,598,000		$ 2,598,000		5,000,000		$ 5,000,000
Impairment of investment in non-marketable equity securities					3,000,000
Arzeda
Marketable Securities [Line Items]
Total non-marketable equity securities					444,000		$ 444,000		$ 1,289,000
Impairment of investment in non-marketable equity securities					$ 900,000
Series A Preferred Stock | MAI | MCRA
Marketable Securities [Line Items]
Number of shares received in exchange for services (in shares)							19,277,914
Series C-1 Preferred Stock | seqWell
Marketable Securities [Line Items]
Non-marketable equity securities purchased (in shares)					88,256		88,256
Series B-2 Preferred Stock | Arzeda
Marketable Securities [Line Items]
Non-marketable equity securities purchased (in shares)					207,070		207,070
Common Stock Warrants | seqWell
Marketable Securities [Line Items]
Non-marketable equity securities purchased (in shares)					44,128		44,128
Total non-marketable equity securities					$ 400,000		$ 400,000
MAI
Marketable Securities [Line Items]
Unrealized gain on non-marketable securities						$ 200,000
MAI | Series B Preferred Stock
Marketable Securities [Line Items]
Number of shares purchased (in shares)	985,545	9,198,423								1,587,049
Payments to acquire other investments	$ 800,000	$ 7,000,000
MAI | Series A Preferred Stock
Marketable Securities [Line Items]
Number of shares purchased (in shares)			1,000,000	1,587,050
Payments to acquire other investments			$ 600,000	$ 1,000,000

Investments in Non-Marketable_4

Investments in Non-Marketable Securities - Carrying Value and Fair Value of Securities (Details) - USD ($) $ in Thousands	Sep. 30, 2023	Dec. 31, 2022	Mar. 31, 2022
Marketable Securities [Line Items]
Total non-marketable equity securities	$ 18,013	$ 20,510
MAI
Marketable Securities [Line Items]
Total non-marketable equity securities	14,671	13,921
seqWell
Marketable Securities [Line Items]
Total non-marketable equity securities	2,598	5,000	$ 5,000
Arzeda
Marketable Securities [Line Items]
Total non-marketable equity securities	444	1,289
Other investments in non-marketable equity securities
Marketable Securities [Line Items]
Total non-marketable equity securities	$ 300	$ 300

Fair Value Measurements (Detail

Fair Value Measurements (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022	Dec. 31, 2022
Summary of financial instruments measured at fair value on a recurring basis
Asset, held-for-sale, not part of disposal group	$ 600,000		$ 600,000
Convertible Debt
Summary of financial instruments measured at fair value on a recurring basis
Credit losses	0	$ 0	0	$ 0
Other-than-temporary impairment losses	0	$ 0	0	$ 0
Money Market Funds
Summary of financial instruments measured at fair value on a recurring basis
Money market funds	65,585,000		65,585,000		$ 77,309,000
Level 1 | Money Market Funds
Summary of financial instruments measured at fair value on a recurring basis
Money market funds	65,585,000		65,585,000		77,309,000
Level 2 | Money Market Funds
Summary of financial instruments measured at fair value on a recurring basis
Money market funds	0		0		0
Level 3 | Money Market Funds
Summary of financial instruments measured at fair value on a recurring basis
Money market funds	$ 0		$ 0		$ 0

Balance Sheets Details - Cash a

Balance Sheets Details - Cash and Cash Equivalents (Details) - USD ($) $ in Thousands	Sep. 30, 2023	Dec. 31, 2022	Sep. 30, 2022
Cash and Cash Equivalents [Line Items]
Adjusted Cost	$ 74,577	$ 113,984	$ 108,689
Money Market Funds
Cash and Cash Equivalents [Line Items]
Adjusted Cost	65,585	77,309
Estimated Fair Value	65,585	77,309
Cash
Cash and Cash Equivalents [Line Items]
Adjusted Cost	$ 9,000	$ 36,700

Balance Sheets Details - Invent

Balance Sheets Details - Inventories (Details) - USD ($) $ in Thousands	Sep. 30, 2023	Dec. 31, 2022
Schedule of Inventory Components
Raw materials	$ 108	$ 108
Work-in-process	0	91
Finished goods	2,197	1,830
Total Inventories	2,305	2,029
Inventory reserves	$ 1,400	$ 1,400

Balance Sheets Details - Proper

Balance Sheets Details - Property and Equipment, net (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022	Dec. 31, 2022
Property, Plant and Equipment [Line Items]
Property and equipment	$ 54,369		$ 54,369		$ 62,435
Less: accumulated depreciation and amortization	(39,087)		(39,087)		(39,821)
Property and equipment, net	15,282		15,282		22,614
Asset, held-for-sale, not part of disposal group	600		600
Asset impairment charges	1,500
Depreciation	1,357	$ 1,405	4,302	$ 3,961
San Carlos
Property, Plant and Equipment [Line Items]
Impairment of leasehold	4,700		4,700
Asset impairment charges	7,700		7,700
Laboratory equipment
Property, Plant and Equipment [Line Items]
Property and equipment	36,376		36,376		39,679
Asset, held-for-sale, not part of disposal group	2,100		2,100
Leasehold improvements
Property, Plant and Equipment [Line Items]
Property and equipment	11,750		11,750		16,633
Computer equipment and software
Property, Plant and Equipment [Line Items]
Property and equipment	3,096		3,096		3,039
Office equipment and furniture
Property, Plant and Equipment [Line Items]
Property and equipment	1,366		1,366		1,345
Construction in progress
Property, Plant and Equipment [Line Items]
Property and equipment	$ 1,781		$ 1,781		$ 1,739

Balance Sheets Details - Goodwi

Balance Sheets Details - Goodwill (Details) $ in Thousands	3 Months Ended	9 Months Ended
	Sep. 30, 2023 USD ($)	Sep. 30, 2023 USD ($)
Goodwill [Roll Forward]
Goodwill, beginning balance		$ 3,241
Impairment	$ (800)	(778)
Goodwill, ending balance	2,463	2,463
Goodwill	$ 2,463	$ 2,463

Balance Sheets Details - Other

Balance Sheets Details - Other Accrued Liabilities (Details) - USD ($) $ in Thousands	Sep. 30, 2023	Dec. 31, 2022
Balance Sheets Details [Abstract]
Accrued professional and outside service fees	$ 5,149	$ 3,495
Accrued purchases	2,644	10,852
Other	1,003	932
Total other accrued liabilities	$ 8,796	$ 15,279

Stock-based Compensation - Equi

Stock-based Compensation - Equity Incentive Plans (Details) - shares	1 Months Ended
	Apr. 30, 2023	Jan. 31, 2023	Jun. 30, 2019	Apr. 22, 2019
2022 Inducement Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares authorized (in shares)		2,000,000
2019 Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares authorized (in shares)			8,100,000
Number of shares available for grant				7,897,144
2019 Amended Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares authorized (in shares)	15,897,144
Maximum number of shares to be issued upon exercise of stock options	22,000,000
Number of additional shares authorized (in shares)	8,000,000

Stock-based Compensation - Empl

Stock-based Compensation - Employee Stock Purchase Plan (Details) - Employee Stock - USD ($)	1 Months Ended
	Jun. 30, 2023	Sep. 30, 2023
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Consecutive offering period	24 months
Purchase price of common stock	85%
Fixed contribution rate	$ 25,000
Number of shares authorized (in shares)		2,000,000

Stock-based Compensation - Stoc

Stock-based Compensation - Stock Options (Details)	9 Months Ended
	Sep. 30, 2023
Stock Options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Percent of voting interests	10%
Purchase price of common stock above minimum threshold	110%
Expiration period	10 years
Award vesting period	4 years
Award, expiration period upon termination of service	3 months
Stock Options | Tranche One
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award vesting period	1 year
Award vesting rights	25%
Stock Options | Tranche Two
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award vesting period	3 years
Award vesting rights	75%
Incentive Stock Options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Purchase price of common stock	100%
Non-Statutory Stock Options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Purchase price of common stock	85%

Stock-based Compensation - Rest

Stock-based Compensation - Restricted Stock Units (Details) - RSUs	9 Months Ended
	Sep. 30, 2023
Tranche One
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award vesting period	3 years
Award vesting rights	33%
Tranche Two
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award vesting period	4 years
Award vesting rights	25%

Stock-based Compensation - PSUs

Stock-based Compensation - PSUs and PBOs (Details) $ in Millions	3 Months Ended			9 Months Ended
	Mar. 31, 2024	Mar. 31, 2023	Mar. 31, 2022	Sep. 30, 2023 USD ($) installment shares
Performance Shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of installments | installment				2
Performance awards, threshold level, number of shares, multiplier				0
Performance Shares | Tranche One
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award vesting rights				50%
Performance Shares | Tranche Two
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award vesting rights				50%
Performance Shares | 2022 PSU And 2022 PBO | Tranche One
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award vesting rights		50%
Performance Shares | 2022 PSU And 2022 PBO | Tranche One | Forecast
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award vesting rights	50%
Performance Shares | 2022 PSU
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Estimated performance goal achievement rate		85%
Performance Shares | 2022 PBO
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Estimated performance goal achievement rate		42.50%
Performance Shares | 2021 PSU And 2021 PBO | Tranche One
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award vesting rights			50%
Performance Shares | 2021 PSU And 2021 PBO | Tranche Two
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award vesting rights			50%
Performance Shares | 2021 PSU
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Estimated performance goal achievement rate			146%
Performance Shares | 2021 PBO
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Estimated performance goal achievement rate			73%
Performance Based Options (PBOs)
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation arrangement by share-based payment award, performance goals achieved, target level, shares eligible to vest, multiplier				100%
Share-based compensation arrangement by share-based payment award, performance goals achieved, threshold level, shares eligible to vest, multiplier				25%
Share-based compensation arrangement by share-based payment award, performance goals achieved, superior level, shares eligible to vest, multiplier				100%
Grants in period (in shares) | shares				0
Compensation not yet recognized, share-based awards other than options				$ 0.1
Performance Share Units (PSUs)
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based payment award, performance goals achieved, threshold level, shares Eligible to vest, multiplier				50%
Share-based compensation arrangement by share-based payment award, performance goals achieved, target level, shares eligible to vest, multiplier				100%
Share-based compensation arrangement by share-based payment award, performance goals achieved, superior level, shares eligible to vest, multiplier				200%
Grants in period (in shares) | shares				0
Stock Options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Compensation not yet recognized, stock options				$ 9.4
Stock Options | Tranche One
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award vesting rights				25%
Stock Options | Tranche Two
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award vesting rights				75%
RSAs and RSUs
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Compensation not yet recognized, share-based awards other than options				$ 6
Performance Stock Units (PSUs)
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Compensation not yet recognized, share-based awards other than options				$ 0.5

Stock-based Compensation - St_2

Stock-based Compensation - Stock-based Compensation Expense (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Stock-based compensation	$ 2,283	$ 4,531	$ 7,808	$ 11,600
Stock options
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Stock-based compensation	1,017	1,679	3,035	3,279
RSUs and RSAs
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Stock-based compensation	942	1,290	3,441	3,785
PSUs
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Stock-based compensation	292	965	1,408	2,279
PBOs
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Stock-based compensation	32	597	(76)	2,257
Cost of product revenue
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Stock-based compensation	60	124	272	367
Research and development
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Stock-based compensation	450	1,045	1,978	3,110
Selling, general and administrative
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Stock-based compensation	$ 1,773	$ 3,362	$ 5,558	$ 8,123

Capital Stock (Details)

Capital Stock (Details) - USD ($) $ / shares in Units, $ in Thousands	1 Months Ended	3 Months Ended		9 Months Ended
	May 31, 2021	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022	Feb. 27, 2023
Class of Stock [Line Items]
Stock options exercised (shares)				214,284	252,100
Weighted average exercise price of stock options exercised (in dollars per share)				$ 1.97	$ 2.43
Proceeds from exercises of stock options				$ 422	$ 612
Sale of stock, securities registered aggregate amount						$ 200,000
Sale of stock, consideration received on transaction, gross				8,700
Net proceeds received				7,900
Costs incurred in connection with offering				721
PSC
Class of Stock [Line Items]
Sale of stock, period	3 years
Sale of stock, value of shares for issuance		$ 41,300		$ 41,300
Sale of stock, maximum selling period	3 years
Sale of stock, commissions, percentage of gross sales price	3%
Issuance of common stock, net of issuance costs (shares)		0	0	3,079,421	0
PSC | Maximum
Class of Stock [Line Items]
Sale of stock, value of shares for issuance	$ 50,000
Sale of stock, commissions and reimbursements, percentage of gross sales price	8%

Commitments and Contingencies -

Commitments and Contingencies - Narrative (Details)			3 Months Ended	9 Months Ended
	Oct. 01, 2023 USD ($)	Jun. 30, 2017 USD ($)	Sep. 30, 2023 USD ($) ft² option	Sep. 30, 2023 USD ($) ft² option	Dec. 31, 2022 USD ($)	Jan. 31, 2021 ft² option
Schedule of Commitments and Contingencies [Line Items]
Area of real estate property (in square feet) | ft²			77,300	77,300
Number of options to extend | option			1	1
Lease obligations			$ 19,979,000	$ 19,979,000	$ 43,638,000
Remeasurement due to lease modification				19,622,000
Asset impairment charges			1,500,000
Impairment				2,997,000
Asset retirement obligation			300,000	300,000	500,000
Indemnification Agreement
Schedule of Commitments and Contingencies [Line Items]
Loss contingency accrual			0	0
Term Loan
Schedule of Commitments and Contingencies [Line Items]
Borrowing capacity		$ 10,000,000
Revolving Credit Facility
Schedule of Commitments and Contingencies [Line Items]
Borrowing capacity		$ 5,000,000
Accounts receivable, borrowing base percentage		80%
Demand Deposits
Schedule of Commitments and Contingencies [Line Items]
Non-current restricted cash			$ 1,100,000	$ 1,100,000	$ 1,100,000
200-220 Penobscot
Schedule of Commitments and Contingencies [Line Items]
Area of real estate property (in square feet) | ft²			28,200	28,200
400 Penobscot
Schedule of Commitments and Contingencies [Line Items]
Area of real estate property (in square feet) | ft²			37,900	37,900
Renewal term			5 years	5 years
501 Chesapeake
Schedule of Commitments and Contingencies [Line Items]
Area of real estate property (in square feet) | ft²			11,200	11,200
Number of options to extend | option			1	1
Renewal term			5 years	5 years
San Carlos
Schedule of Commitments and Contingencies [Line Items]
Area of real estate property (in square feet) | ft²						36,593
Number of options to extend | option						1
Lease term						10 years
Renewal term						5 years
Asset impairment charges			$ 7,700,000	$ 7,700,000
Impairment of leasehold			4,700,000	4,700,000
Impairment			$ 3,000,000	$ 3,000,000
San Carlos | Subsequent Event
Schedule of Commitments and Contingencies [Line Items]
Security deposit	$ 500,000
Lease obligations	3,100,000
Remeasurement due to lease modification	$ 19,600,000

Commitment and Contingencies -

Commitment and Contingencies - Schedule of Right-of-use Assets and Lease Obligations (Details) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022
Operating Lease, Right-of-Use Asset [Roll Forward]
Beginning balance, lease obligation - operation leases, net	$ 39,263
Amortization of right-of-use assets	(3,647)	$ (3,618)
Additions	898
Remeasurement due to lease modification	(19,622)
Impairment	(2,997)
Right-of-use assets - Operating leases, net, at September 30, 2023	13,895
Operating Lease, Liability [Roll Forward]
Beginning balance, lease obligations - operating leases, net	43,638
Lease payments	(5,668)	$ (4,658)
Interest accretion	1,631
Remeasurement due to lease modification	(19,622)
Ending balance, lease obligations - operating leases, net	$ 19,979

Commitments and Contingencies_2

Commitments and Contingencies - Lease Cost (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Lease, Cost [Abstract]
Finance lease costs	$ 0	$ 0	$ 0	$ 18
Operating lease costs	1,618	1,831	5,278	5,491
Short-term lease costs	0	0	0	40
Total lease cost	1,618	1,831	5,278	5,549
Variable lease cost	$ 0	$ 0	$ 0	$ 0

Commitments and Contingencies_3

Commitments and Contingencies - Other Lease Information (Details)	Sep. 30, 2023
Commitments and Contingencies Disclosure [Abstract]
Weighted-average remaining lease term (in years)	3 years 4 months 24 days
Weighted-average discount rate	6.70%

Commitments and Contingencies_4

Commitments and Contingencies - Cash Paid for Lease Obligations (Details) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022
Commitments and Contingencies Disclosure [Abstract]
Lease payments	$ 5,668	$ 4,658

Commitments and Contingencies_5

Commitments and Contingencies - Maturity Analysis of Operating Lease (Details) - USD ($) $ in Thousands	Sep. 30, 2023	Dec. 31, 2022
Operating Leases
2023 (remaining 3 months)	$ 4,229
2024	4,727
2025	4,868
2026	5,014
2027	2,533
Thereafter	1,078
Total minimum lease payments	22,449
Less: imputed interest	2,470
Lease obligations	19,979	$ 43,638
Current portion of lease obligations - Operating leases	6,764	5,360
Long-term lease obligations - Operating leases	$ 13,215	$ 38,278

Commitments and Contingencies_6

Commitments and Contingencies - Other Commitments (Details) - Facility maintenance agreement $ in Thousands	Sep. 30, 2023 USD ($)
Other Commitments [Line Items]
Total	$ 1,084
2023 (Remaining 3 Months)	1,039
2024 and Thereafter	$ 45

Related Party Transactions (Det

Related Party Transactions (Details) - USD ($) $ in Thousands	1 Months Ended				3 Months Ended	9 Months Ended
	Mar. 31, 2023	Sep. 30, 2021	Apr. 30, 2021	Jun. 30, 2020	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022	Jun. 30, 2022
Related Party Transaction [Line Items]
Payments to acquire other investments						$ 1,191	$ 5,300
MAI | MCRA
Related Party Transaction [Line Items]
Research and development revenue from transactions with MAI					$ 1,000		1,200
MAI | MCRA | Product revenue
Related Party Transaction [Line Items]
Research and development revenue from transactions with MAI					$ 200		$ 400
MAI | Series A Preferred Stock
Related Party Transaction [Line Items]
Number of shares purchased (in shares)			1,000,000	1,587,050
Payments to acquire other investments			$ 600	$ 1,000
MAI | Series B Preferred Stock
Related Party Transaction [Line Items]
Number of shares purchased (in shares)	985,545	9,198,423						1,587,049
Payments to acquire other investments	$ 800	$ 7,000

Segment, Geographical and Oth_3

Segment, Geographical and Other Revenue Information - Narrative (Details) $ in Thousands	3 Months Ended	9 Months Ended
	Sep. 30, 2023 USD ($)	Sep. 30, 2023 USD ($) segment
Segment Reporting [Abstract]
Number of operating segments		2
Number of reportable segments		2
Goodwill impairment | $	$ 800	$ 778

Segment, Geographical and Oth_4

Segment, Geographical and Other Revenue Information - Segment Reporting (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Segment Reporting Information [Line Items]
Total revenues	$ 9,277	$ 34,470	$ 43,582	$ 108,215
Cost of product revenue	2,249	9,786	9,947	29,577
Research and development	13,662	21,821	47,651	60,410
Selling, general and administrative	12,302	13,499	41,066	39,859
Restructuring charges	3,140	0	3,284	0
Asset impairment and other charges	9,984	0	9,984	0
Total costs and operating expenses	41,337	45,106	111,932	129,846
Loss from operations	(32,060)	(10,636)	(68,350)	(21,631)
Loss before income taxes	(34,899)	(9,984)	(69,014)	(20,863)
Goodwill impairment	800		778
Stock-based compensation	2,283	4,531	7,808	11,600
Performance Enzymes
Segment Reporting Information [Line Items]
Goodwill impairment			0
Novel Biotherapeutics
Segment Reporting Information [Line Items]
Goodwill impairment			778
Product revenue
Segment Reporting Information [Line Items]
Total revenues	5,395	28,042	24,807	93,376
Research and development revenue
Segment Reporting Information [Line Items]
Total revenues	3,882	6,428	18,775	14,839
Operating segments
Segment Reporting Information [Line Items]
Total revenues	9,277	34,470	43,582	108,215
Cost of product revenue	2,249	9,786	9,947	29,577
Research and development	12,523	20,637	44,029	57,112
Selling, general and administrative	2,134	4,679	8,106	13,496
Restructuring charges	2,399	0	2,544	0
Asset impairment and other charges	778	0	778	0
Total costs and operating expenses	20,083	35,102	65,404	100,185
Loss from operations	(10,806)	(632)	(21,822)	8,030
Stock-based compensation	2,283	4,531
Operating segments | Performance Enzymes
Segment Reporting Information [Line Items]
Total revenues	8,710	31,146	37,503	100,774
Cost of product revenue	2,249	9,786	9,947	29,577
Research and development	8,146	6,782	24,100	19,833
Selling, general and administrative	1,748	3,791	6,578	11,208
Restructuring charges	1,182	0	1,182	0
Asset impairment and other charges	0	0	0	0
Total costs and operating expenses	13,325	20,359	41,807	60,618
Loss from operations	(4,615)	10,787	(4,304)	40,156
Stock-based compensation	903	1,593	2,861	4,776
Operating segments | Novel Biotherapeutics
Segment Reporting Information [Line Items]
Total revenues	567	3,324	6,079	7,441
Cost of product revenue	0	0	0	0
Research and development	4,377	13,855	19,929	37,279
Selling, general and administrative	386	888	1,528	2,288
Restructuring charges	1,217	0	1,362	0
Asset impairment and other charges	778	0	778	0
Total costs and operating expenses	6,758	14,743	23,597	39,567
Loss from operations	(6,191)	(11,419)	(17,518)	(32,126)
Stock-based compensation	(235)	414	98	1,182
Operating segments | Product revenue
Segment Reporting Information [Line Items]
Total revenues	5,395	28,042	24,807	93,376
Operating segments | Product revenue | Performance Enzymes
Segment Reporting Information [Line Items]
Total revenues	5,395	28,042	24,807	93,376
Operating segments | Product revenue | Novel Biotherapeutics
Segment Reporting Information [Line Items]
Total revenues	0	0	0	0
Operating segments | Research and development revenue
Segment Reporting Information [Line Items]
Total revenues	3,882	6,428	18,775	14,839
Operating segments | Research and development revenue | Performance Enzymes
Segment Reporting Information [Line Items]
Total revenues	3,315	3,104	12,696	7,398
Operating segments | Research and development revenue | Novel Biotherapeutics
Segment Reporting Information [Line Items]
Total revenues	567	3,324	6,079	7,441
Corporate, non-segment
Segment Reporting Information [Line Items]
Total costs and operating expenses	(22,736)	(7,947)	(42,890)	(24,940)
Unallocated depreciation and amortization	(1,357)	(1,405)	(4,302)	(3,953)
Stock-based compensation	$ 1,615	$ 2,524	$ 4,849	$ 5,642

Segment, Geographical and Oth_5

Segment, Geographical and Other Revenue Information - Concentration Risk (Details) - Customer Concentration Risk	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022	Dec. 31, 2022
Revenue | Customer A
Concentration Risk [Line Items]
Concentration risk, percentage	20%
Revenue | Customer B
Concentration Risk [Line Items]
Concentration risk, percentage		39%	15%	54%
Revenue | Customer C
Concentration Risk [Line Items]
Concentration risk, percentage		13%
Revenue | Customer D
Concentration Risk [Line Items]
Concentration risk, percentage			10%
Revenue | Customer E
Concentration Risk [Line Items]
Concentration risk, percentage			10%
Accounts Receivable | Customer B
Concentration Risk [Line Items]
Concentration risk, percentage					53%
Accounts Receivable | Customer D
Concentration Risk [Line Items]
Concentration risk, percentage			15%
Accounts Receivable | Customer E
Concentration Risk [Line Items]
Concentration risk, percentage					10%
Accounts Receivable | Customer F
Concentration Risk [Line Items]
Concentration risk, percentage			38%
Accounts Receivable | Customer G
Concentration Risk [Line Items]
Concentration risk, percentage			17%

Segment, Geographical and Oth_6

Segment, Geographical and Other Revenue Information - Revenues by Geographic Area (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Segment Reporting Information [Line Items]
Total revenues	$ 9,277	$ 34,470	$ 43,582	$ 108,215
Americas
Segment Reporting Information [Line Items]
Total revenues	4,278	4,822	10,798	12,167
EMEA
Segment Reporting Information [Line Items]
Total revenues	3,191	5,987	14,630	14,805
APAC
Segment Reporting Information [Line Items]
Total revenues	$ 1,808	$ 23,661	$ 18,154	$ 81,243

Segment, Geographical and Oth_7

Segment, Geographical and Other Revenue Information - Long-Lived Assets by Geographic Area (Details) - USD ($) $ in Thousands	Sep. 30, 2023	Dec. 31, 2022
United States
Geographic Areas, Long-Lived Assets [Abstract]
Long-lived assets	$ 29,177	$ 61,877

Segment, Geographical and Oth_8

Segment, Geographical and Other Revenue Information - Goodwill (Details) - USD ($) $ in Thousands	3 Months Ended	9 Months Ended
	Sep. 30, 2023	Sep. 30, 2023
Goodwill [Roll Forward]
Goodwill, beginning balance		$ 3,241
Impairment	$ (800)	(778)
Goodwill, ending balance	2,463	2,463
Performance Enzymes
Goodwill [Roll Forward]
Goodwill, beginning balance		2,463
Impairment		0
Goodwill, ending balance	2,463	2,463
Novel Biotherapeutics
Goodwill [Roll Forward]
Goodwill, beginning balance		778
Impairment		(778)
Goodwill, ending balance	$ 0	$ 0

Allowance for Credit Losses - A

Allowance for Credit Losses - Analysis of Allowance for Credit Losses (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Financing Receivable, Allowance for Credit Loss [Roll Forward]
Balance at beginning of period	$ 133	$ 109	$ 163	$ 416
Provision for credit losses	0	0	0	0
Write-offs	0	0	30	257
Adjustment to the existing allowance	0	0	0	50
Balance at end of period	$ 133	$ 109	$ 133	$ 109

Allowance for Credit Losses - S

Allowance for Credit Losses - Summary of Finance Receivables by Aging Category (Details) - USD ($) $ in Thousands	Sep. 30, 2023	Dec. 31, 2022
Financing Receivable, Allowance for Credit Loss [Line Items]
Accounts receivable	$ 11,629	$ 31,904
Current
Financing Receivable, Allowance for Credit Loss [Line Items]
Accounts receivable	6,835	28,896
31-60 Days
Financing Receivable, Allowance for Credit Loss [Line Items]
Accounts receivable	4,690	1,747
61-90 Days
Financing Receivable, Allowance for Credit Loss [Line Items]
Accounts receivable	22	469
91 Days and over
Financing Receivable, Allowance for Credit Loss [Line Items]
Accounts receivable	82	792
Total over 31 Days
Financing Receivable, Allowance for Credit Loss [Line Items]
Accounts receivable	$ 4,794	$ 3,008

Restructuring Charges - Narrati

Restructuring Charges - Narrative (Details) - USD ($) $ in Thousands	1 Months Ended		3 Months Ended		9 Months Ended
	Jul. 31, 2023	Nov. 30, 2022	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Restructuring Cost and Reserve [Line Items]
Restructuring charges			$ 3,140	$ 0	$ 3,284	$ 0
Employee-related Liabilities, Current
Restructuring Cost and Reserve [Line Items]
Restructuring reserve			1,900		1,900
Employee Severance
Restructuring Cost and Reserve [Line Items]
Restructuring charges			3,100
One-time Termination Benefits
Restructuring Cost and Reserve [Line Items]
Restructuring and related cost, number of positions eliminated, period percent	25%	18%
Restructuring charges			$ 0		$ 200

Assets Held For Sale (Details)

Assets Held For Sale (Details) $ in Millions	3 Months Ended
	Sep. 30, 2023 USD ($)
Discontinued Operations and Disposal Groups [Abstract]
Asset impairment charges	$ 1.5
Asset, held-for-sale, not part of disposal group	$ 0.6